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(57) ABSTRACT 
Various embodiments provide methods and related composi-
tions for increasing the population size ofhematopoietic stem 
cells (HSCs) in patients that may benefit from reconstitution 
of stem cells and/or differentiated cells of the blood lineage. 
The present methods enable the production ofHSCs ex vivo 
and in vivo by reducing latexin expression and/or latexin 
activity within HSC exposed to various antagonists. Inhibi-
tion of latexin expression and/or latexin activity by various 
antagonists can promote HSC proliferation and/or inhibit 
HSC apoptosis. Antagonists that can reduce latexin expres-
sion and/or latexin activity can be utilized to regenerate 
endogenous HSCs within patients affected with disorders, 
diseases, cancers, or therapies for such conditions, that result 
in the depletion or reduction in HSCs. 
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EX VIVO AND IN VIVO METHODS AND 
RELATED COMPOSITIONS FOR 
REGENERATING HEMATOPOIETIC STEM 
CELL POPULATIONS 
CROSS-REFERENCES 
This application is a divisional ofU.S. application Ser. No. 
11/540,641, filed Oct. 2, 2006, which is a non-provisional 
application that claims priority under 35 U.S.C. § 119 to U.S. 
Provisional Application No. 60/722,755 entitled MANIPU-
LATION OF ADULT STEM CELL POPULATION SIZES 
BY LATEXIN and filed on Sep. 30, 2005, the entire content 
of which are hereby incorporated by reference. 
STATEMENT OF GOVERNMENT INTEREST 
2 
(e.g., typically less than 8 weeks in a mouse) prior to under-
going full differentiation. HSCs can differentiate into 
hematopoietic progenitor cells ("HPCs") that can further dif-
ferentiate into clonogenic cells, or cells of a single lineage. 
5 For example, the differentiation of common lymphoid pro-
genitors ("CLPs") can produce T lymphocytes ("T cells"), B 
lymphocytes ("B cells"), and natural killer cells ("NKs"). The 
differentiation of common myeloid progenitors ("CMPs") 
can generate blood cells of other lineages, including erythro-
10 cytes, macrophages, granulocytes, and platelets. The mainte-
nance of mature blood-borne cells in the peripheral circula-
tion is critical for various processes, including oxygen 
delivery and immunological protection. 
Bone marrow transplantation ("BMT") and hematopoietic 
15 stem cell transplantation ("HSCT") can be effective for the 
treatment of diseases of the blood, diseases of the bone mar-
row, cancers of the blood, and cancers of the bone marrow, 
including various types of anemia, leukemia, and immuno-This invention has been made with Government support 
under grant number ROIAG024950, awarded by the National 
Institute on Aging. The government has certain rights in the 20 
logical disorders. For example, obtaining HSCs by bone mar-
row harvesting from donors can be technically challenging in 
that harvesting sufficient material from the bone marrows of invention. 
TECHNICAL FIELD 
donors involves multiple insertions oflarge needles to obtain 
sufficient amount of stem cells. Methods for regenerating 
HSCs can be useful for treating patients affected by various 
The present invention relates to methods for regenerating 
adult hematopoietic stem cells (HSCs) and related composi-
tions by reducing/inhibiting latexin expression and/or latexin 
activity. 
25 types of disorders, diseases, or cancers that deleteriously 
affect the number of endogenous HSCs within a patient. 
INCORPORATION-BY-REFERENCE & TEXTS 30 
SUMMARY OF THE INVENTION 
An ex vivo method for producing a renewed population of 
hematopoietic stem cells (HSCs) is provided, in which a first 
HSC population from a donor is obtained, the first HSC 
population is contacted with an antagonist that reduces 
latexin expression and/or latexin activity, and the HSC popu-
The material on the accompanying CD-R is hereby incor-
porated by reference into this application. The accompanying 
compact disc contains one file, 1028750-000249 
HSCS.ST25.txt, which was created on Oct. 2, 2006. The file 
named 1028750-000249 HSCS.ST25.txt is 5 KB. The file can 
be accessed using Microsoft Word on a computer that uses 
Windows OS. 
35 lation is cultured under in vitro conditions that can promote 
cell proliferation and/or inhibit apoptosis to obtain a second 
HSC population that comprises a progeny of the first HSC 
population. 
A method for reconstituting a recipient host with a HSC 
BACKGROUND OF THE INVENTION 
Hematopoiesis is a complex process for producing mul-
tiple and distinct lineages ofblood-borne cells throughout the 
life span of an organism. Hematopoietic stem cells ("HSCs") 
represent a subset of undifferentiated cells that resides pre-
dominantly in the bone marrow of adult mammals. HSCs, as 
40 population generated ex vivo is provided, in which a first HSC 
population from a donor is obtained, the first HSC population 
is contacted with an antagonist that reduces latexin expres-
sion and/or latexin activity, the HSC population is cultured 
under in vitro conditions that can promote cell proliferation 
45 and/or inhibit apoptosis to obtain a second HSC population 
that comprises a progeny of the first HSC population, and the 
second HSC population is transplanted to the recipient host in 
need ofHSC reconstitution. 
a population, are capable of self-renewal by maintaining a 
sufficient number of HSCs within an organism's bone mar-
row as a reservoir of uncommitted cells that can be further 
differentiated into various types of new blood cells. Such 50 
newly generated blood cells emerge from the bone marrow 
and enter the circulatory system in order to continuously 
replace mature/aging circulating blood cell types. The ability 
of HSCs, as a population, to differentiate and to give rise to 
cells of multi-lineages is critical for the preservation of an 55 
organism. 
In order for the maintenance of steady-state hematopoiesis, 
a balance must be achieved between the rate of self-genera-
tion (i.e., for maintaining a steady supply of HSCs) and the 
rate of differentiation (i.e., for replenishing senescent cells). 60 
Hematopoiesis occurs as a developmental continuum in that a 
given population of HSCs is representative of a heteroge-
neous mixture of cells, mainly composed oflong-term HSCs 
("LT-HSCs") and short-term HSCs ("ST-HSCs"). LT-HSCs 
are stem cells that have the capacity for self-renewal through- 65 
out the life span of an organism. However, ST-HSCs exhibit 
transient self-renewal properties for a limited period of time 
A method for reconstituting a recipient host with a HSC 
population generated in vivo is provided, in which the recipi-
ent host is administered with a pharmaceutical composition 
comprising an antagonist that reduces latexin expression and/ 
or latexin activity. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 illustrates various biochemical pathways mediated 
by latexin that may be involved in the regulation of HSC 
proliferation in mammals, as described in Example 1. 
FIG. 2 illustrates a genomic map of congenic intervals 
identified in reciprocal Chr.3 congenic mouse strains, as 
described in Example 1. 
FIG. 3 illustrates a genome-wide linkage analysis based on 
GeneNetwork that associates the trait regulating HSC popu-
lation size with three quantitative trait loci (QTL) on Chro-
mosomes (Chr) 3, 5, and 18, respectively, as described in 
Example 4. 
US 9,284,530 B2 
3 
FIG. 4A illustrates the CAFC day 35 frequency observed 
for femur cells of Chr3 congenic mice compared to back-
ground mice, as described in Example 5. 
4 
(HSCs) within a patient in need of HSC renewal. For 
example, the present methods are useful for the treatment of 
patients affected with disorders, diseases, and/or cancers that 
FIG. 4B illustrates the CAFC day 35 frequency observed 
for LSK cells of Chr3 congenic mice compared to back- 5 
ground mice, as described in Example 5. 
deleteriously compromise the number of endogenous HSCs 
and differentiated forms of such HSCs within patients. 
Examples of disorders, diseases, and/or cancers contem-
FIG. 4C illustrates the effect ofD2 alleles on the number of 
long-termrepopulating HSCs in B.D Chr3 mice, as described 
in Example 5. 
FIG. SA illustrates that D2 alleles confer an increase in 10 
plated for treatment by the present methods and compositions 
include diseases of the blood, diseases of the bone marrow, 
cancers of the blood, and cancers of the bone marrow, includ-
ing various types of anemia, leukemia, immunological disor-
ders, thalassemia major, sickle-cell disease, myelodysplastic HSC replication and that B6 alleles confer a decrease in HSC 
replication, as described in Example 6. 
FIG. SB illustrates the effect ofChr3 QTL on the cell-cycle 
kinetics of hematopoietic progenitor cells (HPCs), as 
described in Example 6. 
FIG. SC illustrates that D2 alleles of the Chr 3 QTL confer 
HSCs with higher self-renewal capability, as described in 
Example 7. 
FIG. SD illustrates bone marrow LSK cells subject to apo-
ptosis as detected by Annexin V-staining, as described in 
Example 8. 
FIG. SE illustrates the effect of Chr 3QTL on apoptosis of 
LSK cells in steady-state B6 D2 and Chr3 congenic bone 
marrows, as described in Example 8. 
FIG. 6A illustrates Lxn mRNA expression in congenic 
LSK cells compared with B6 and D2 cells, as described in 
Example 10. 
syndrome, lymphoma, aplastic anemia, and multiple 
myeloma. Patients that may benefit from treatments that uti-
lize the present methods and related compositions include 
15 candidates for bone marrow transplantation ("BMT") and 
hematopoietic stem cell transplantation ("HSCT"). Trans-
plantation therapies can be effective for the treatment of vari-
ous types of leukemia and any disorder/disease/cancer for 
which patients are subjected to radiotherapy and/or chemo-
20 therapy. The renewed or regenerated population ofHSCs that 
can be induced by the present methods and compositions are 
useful for various applications, including regenerative medi-
cine, tissue engineering, tissue repair, cancer therapy, and 
gene therapy. As described in the following embodiments, a 
25 given HSC population obtained from a donor or within a 
recipient host (i.e., a patient) can be induced to proliferate 
and/or to suppress apoptosis by providing antagonistic com-
pounds/compositions that can inhibit latexin expression and/ 
or latexin activity. 
FIG. 6B illustrates quantitation ofLxn transcripts by real-
time PCR in peripheral blood leukocytes, whole bone mar-
row, Lin-negative bone marrow cells, and LSK stem cells, as 30 
described in Example 11. I. Definitions 
FIG. 6C illustrates immunoreactivity between the anti-
mouse LXN antibody and a protein (29 kD) from bone mar-
row cells by a Western Blot, as described in Example 12. 
FIG. 6D illustrates the levels ofLXN protein in whole bone 35 
marrow and Lin-negative cells, as described in Example 12. 
As used throughout the specification and the appended 
claims, the terms listed below have the following meanings, 
wherein "a" means one or more: 
The terms "hematopoietic stem cells" ("HSCs") refer to a 
heterogeneous mixture of undifferentiated progenitor stem 
cells, mainly composed oflong-term HSCs ("LT-HSCs") and 
short-term HSCs ("ST-HSCs"). LT-HSCs are undifferenti-
ated stem cells that have the capacity for self-renewal 
throughout the life span of an organism. ST-HSCs are undif-
FIG. 7A illustrates various QTLs that may be involved in 
the regulation ofLxn expression, as described in Example 13. 
FIG. 7B illustrates a CpG island analysis in the upstream 
sequence of Lxn open-reading frame, as described in 40 
Example 13. 
FIG. SA illustrates a schematic for in vitro infection of 
bone marrow cells with retroviral vectors containing either 
GFP or Lxn (Lxn-GFP), and subsequent transplantation into 
irradiated mouse recipients, as described in Example 14. 
FIG. SB illustrates results of a Western blot analysis of 
GFP+ cells sorted from the BM of the recipient mice trans-
planted with either Lxn-GFP or GFP-transduced cells, as 
described in Example 14. 
FIG. SC illustrates results ofCAFC day35 frequency assay 
ofD2 bone marrow cells transduced with either GFP control 
or Lxn-GFP, as described in Example 14. 
FIG. SD illustrates results of long-term repopulating cells 
(LTRC) frequency assay of B.D Chr.3 congenic BM cells 
transduced with either GFP control or Lxn-GFP, as described 
in Example 14. 
FIG. 9A illustrates exemplary SiRNAs transfected into 
NIH3T3 cells, as described in Example 15. 
FIG. 9B illustrates the results of sequence-specific SiRNA-
mediated inhibition of latexin mRNA expression in mouse 
adult stem cells that resulted in HSC proliferation and HSC 
apoptotic inhibition, as described in Example 15. 
DETAILED DESCRIPTION OF THE INVENTION 
Various embodiments provide methods and related com-
positions useful for reconstituting hematopoietic stem cells 
ferentiated stem cells that have the capacity for self-renewal 
for a limited time prior to full differentiation into a specific 
lineage. For example, HSCs can differentiate into hematopoi-
45 etic progenitor cells ("HPCs") that can further differentiate 
into clonogenic cells, or cells of a single lineage, that repre-
sent a subset of a hematopoietic lineage. HSCs include non-
embryonic stem cells isolated from post-natal animals. HSCs 
include "pluripotent adult stem cells" isolated from the bone 
50 marrows of mammals that are capable of differentiating into 
tissues of all three germ or dermal layers, such as the meso-
derm, endoderm, and ectoderm. A "pluripotent stem cell" 
refers to a stem cell that exhibits the capacity to grow into any 
type of cell that constitutes an organism. A pluripotent cell 
55 can be self-renewing and can remain dormant/quiescent 
within a tissue. HSCs include "multipotent stem cells" that 
exhibit the capacity to grow into any subset of cells that 
constitute an organism. HSCs include undifferentiated stem 
cells that exhibit a distinct profile of cell surface markers, 
60 including the following combination of markers: Thy-1 10 Sea-
l+ Lineage- c-kit+; or CD 150+ CD48- Sea-l+ Lineage- c-kit+; 
orThy-1 1° CD150+ CD48- Sea-l+ Lineage- c-kit+ (Kiel eta!., 
Cell, Vol. 121, p 1109-1121 (2005)). HSCs that express the 
combination of human counterparts for these markers are 
65 preferably contemplated. The following references are herein 
incorporated by reference in their entirety: Cheshier et a!., 
P.N.A.S., Vol. 96, p 3120-3125 (1999); Eckfeldtetal., Nature, 
US 9,284,530 B2 
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Vol. 6, p 726-737 (2005); Wright et. a!., Science, Vol. 94, p 
1933-1936 (2001 ); and Preston eta!., J. Clin. Pathol. Vol. 56, 
p 86-96 (2003). 
The term "first HSC population" refers to HSCs obtained 
from a donor, wherein the first HSC population expresses cell 
surface markers as described in [0036]. 
The term "second HSC population" refers to the progeny of 
the first HSC population produced by in vitro cell prolifera-
tion under in vitro conditions, wherein the second HSC popu-
lation expresses cell surface markers as described in [0036]. 
The term "latexin" ("Lxn") refers to the Lxn gene, iso-
forms/variants of the Lxn gene, and gene products derived 
from the Lxn gene, including messenger RNA and protein. 
The sense-strand of a human latexin eDNA is provided as 
SEQ ID NO: 1. A human latexin protein sequence is provided 
as SEQ ID N0:2. Latexin isoforms/variants include genes 
containing exon sequences having at least about 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
similarity to SEQ ID NO: 1; genes containing exon sequences 
having at least about 70%,75%,80%, 85%, 90%, 95%,96%, 
97%, 98%, or 99% sequence identity to SEQ ID NO: 1; those 
sequences encoded by genes containing exon sequences hav-
ing at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, or 99% sequence similarity to SEQ ID NO: 1; 
those sequences encoded by genes containing exon 
sequences having at least about 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID 
NO: 1; those sequences having at least about 70%, 75%, 80%, 
85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence similar-
ity to SEQ ID N0:2; and those sequences having at least 
about70%, 75%,80%,85%,90%,95%,96%,97%, 98%,or 
99% sequence identity to SEQ ID N0:2. Latexin isoforms/ 
variants include mammalian homo logs listed in Tables 1-3 as 
described in [0076]. Examples of latexin isoforms/variants 
include the carboxypeptidase inhibitor (CARIN) described in 
U.S. Pat. No. 5,998,373. 
6 
ing HSC cell proliferation (i.e., HSC self-renewal) and/or by 
suppressing HSC apoptosis, as seen in B.D Chr3 congenic 
mice. In contrast, the B6 alleles conferred a decrease in HSC 
population size. Differential expression levels conferred by 
these alleles correlated with the latexin ("Lxn") gene locus. 
Differentiallatexin expression levels were shown to inversely 
correlate with HSC population size, based on experimental 
data obtained utilizing oligonucleotide arrays (e.g., microar-
rays), real-time PCR, and Western blots. Ectopic expression 
10 of latexin protein from a retroviral construct resulted in a 
decrease in stem cell population size. Clusters of single nucle-
otide polymorphisms (SNPs) were identified upstream of the 
Lxn transcriptional start site. At least two of these clusters 
15 
appear to be associated with potential binding sites fortran-
scription factors involved in hematorpoietic stem cell regula-
tion. Thus, promoter polymorphisms between B6 and D2 
alleles appear to affect Lxn gene expression, and conse-
quently, to influence HSC population size. The results of 
20 these experiments are presented in FIGS. 1-9 and are further 
described in Examples 1-15. 
Latexin was identified initially as an antigen expressed 
within the rat cerebral cortex. Latexin mRNA and protein (29 
kDa) have been shown by others to be expressed in neural and 
25 non-neural tissues. Latexin exhibits inhibitory activity 
against rat carboxypeptidase AI ("CPA!"), carboxypeptidase 
A2 ("CPA2), and mast-cell CPA (Uratani eta!., Biochem. J., 
Vol346: 817-826 (2000). CPA and CPB are pancreatic zinc-
containing proteolytic enzymes that catalyze the hydrolysis 
30 of the carboxyl-terminal peptide bond within polypeptide 
chains. Carboxypeptidase activities can be regulated either by 
endogenous protein inhibitors or by enzymatic cleavage of a 
segment of a propeptide that releases the active form of the 
carboxypeptidase. Both latexin and Tissue Carboxypeptidase 
35 Inhibitor (TCI) are examples of endogenous protein inhibi-
tors of carboxypeptidases. Latexin and TCI contain several 
potential phosphorylation sites, and both are expressed and 
localized in the cytosol of a number of tissues, including the 
The term "antagonist" refers to any compound or compo-
sition that can inhibit the expression and/or the activity of 
latexin and latexin isoforms, including sequence-specific 
polynucleotides that can interfere with the transcription of 40 
endogenous latexin gene; sequence-specific polynucleotides 
that can interfere with the translation of latexin mRNA tran-
scripts (e.g., siRNAs, ribozymes ); sequence-specific 
polypeptides that can interfere with the protein stability of 
latexin, the enzymatic activity of latexin, and/or the binding 
activity oflatexin with respect to substrates and/or regulatory 
proteins; and small molecule compounds that can interfere 
with the protein stability oflatexin, the enzymatic activity of 
latexin, and/or the binding activity of latexin. An effective 
antagonist can promote HSC proliferation by at least 25%, 
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 
80%, 85%, 90%, 95%, or 100%. An effective antagonist can 
suppress HSC apoptosis by at least 25%, 30%, 35%, 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
95%, or 100%. 
brain, the lung, and the digestive tract. 
FIG. 1 illustrates various biochemical pathways mediated 
by latexin that may be involved in the regulation of HSC 
proliferation in mammals. Lxn is the only known endogenous 
carboxypeptidase A (CPA) inhibitor in mammals. Structural 
similarity between latexin and cystatins that inhibit cathep-
45 sins in the lysosomal protein degradation pathway suggests 
an inflammatory role of latexin in activated macrophages. 
Thus, latexin may be involved in the metabolism of specific 
proteins that are essential for HSC functions. Lxn appears to 
exhibit two potential Ca2+/calmodulin-dependent protein 
50 kinase sites and one c-GMP-dependent protein kinase phos-
phorylation site. Thus, the c-GMP/PKG and/or calcium/ 
calmodulin signaling pathways may be involved in the Lxn-
mediated regulation of HSCs. The physical structure of 
latexin includes two nearly identical domains that have high 
55 conformational homology with the cystatins that can inhibit 
cathepsins in the lysosomal protein degradation pathway. 
Thus, Lxn appears to have an inflammatory role in activated 
macrophages, and to be involved in the metabolism of spe-
cific proteins that are essential for HSC functions. The 
II. Regulation of Cell Cycling, Apoptosis, and 
Proliferation of Hematopoietic Stem Cells (HSCs) 
Mediated by Latexin 
The present inventors have identified a quantitative trait 
loci ("QTL") that confers variation in HSC numbers in young 
and adult C57BL/6 (B6) and DBA/2 (D2) mice. By utilizing 
reciprocal Chromosome 3 congenic mice derived from these 
two parental strains, such as B.D Chr3 and D.B Chr3 mice, 
the present inventors have demonstrated that introgressed D2 
alleles confer an increase in HSC population size by enhanc-
60 c-GMP/PKG and/or calcium/calmodulin signaling pathways 
may be involved in Lxn-mediated regulation ofHSCs based 
on the fact that Lxn contains two potential Ca2+/calmodulin 
dependent protein kinase sites and one c-GMP-dependent 
protein kinase phosphorylation site. These possible pathways 
65 may act synergistically or independently in the regulation of 
HSC cycling, apoptosis, and/or proliferation that affect HSC 
population size. 
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The mechanism for transcriptional regulation of latexin 
appears to be related to the unique molecular architecture of 
the Lxn gene locus, that includes multiple SNPs within poten-
tial regulatory regions. The Lxn gene locus is located within 
an intron of Gfml, a gene that encodes a translational elon-
gation factor in mitochondria. Because Gfml was not differ-
entially expressed amongst the congenic and background 
strains investigated, the differential transcriptional regulation 
of the embedded Lxn was unique. The specific promoter 
and/or enhancer regions of Lxn appear to be highly gene- 10 
specific and to enable differential gene regulation. A potential 
mechanism for differential gene expression between B6 and 
D2 alleles is suggested by the identification of clusters of 
confirmed SNPs sites within the potential promoter region of 
Lxn that are spatially concordant with two putative binding 15 
sites for transcription factors known to regulate stem cells. 
For example, a cluster of SNPs (SNPs 1-3) in the canonical 
Lxn promoter region is consistent with a region identified by 
ESPEER as potentially possessing regulatory activity. The 
SNP2 is located in the middle of the canonical core binding 20 
site in one of two adjacent potential binding sites for the 
transcription factor CBFl. The CBFl is associated with the 
Notch-signaling pathway, known to be play a role in the 
regulation of stem cell population size. The SNPs 10 and 11 
are in close proximity, or reside within potential regulatory 25 
regions, identified by ESPERR and TraFaC. The HNFl/ 
TCFl, a transcription factor with two adjacent binding sites 
close to SNPll, can mediate events downstream of the 
canonical Wnt/beta-catenin-signaling pathway known to be 
involved in HSC regulation and to interact with the Notch- 30 
signaling pathway. 
III. Methods for Inhibiting Latexin Expression 
and/ or Latexin Activity 
8 
erably obtained from human donors, however, non-human 
donors are also contemplated, including non-human pri-
mates, pigs, cows, horses, cats, and dogs. A purified popula-
tion of HSCs may be obtained by utilizing various methods 
known by persons skilled in the art and described in U.S. Pat. 
No. 5,677,136; and U.S. Patent Publication No. 2006/ 
0040389, which are incorporated by reference in their 
entirety. 
Suitable antagonists include SiRNAs, ribozymes, anti-
sense oligodeoxynucleotides, and small molecule com-
pounds that can reduce latexin expression and/or latexin 
activity. Examples of suitable antagonists and methods for 
producing or identifYing such antagonists are described 
below in Subsection C. A therapeutically effective latexin 
antagonist can promote HSC proliferation and/or suppress 
apoptosis by at least 25%. Suitable antagonists are further 
defined above in Subsection I. 
Contacting the first HSC population with an antagonist that 
reduces latexin expression and/or latexin activity can pro-
mote cell proliferation and/or inhibit apoptosis provided that 
the first HSC population is cultured under suitable in vitro 
conditions. Latexin expression and/or latexin activity include 
intracellular processes that regulate latexin promoter activa-
tion, transcriptional activation, transcriptional termination, 
post-transcriptional processing, translational initiation, trans-
lational elongation, translational termination, and post-trans-
lational modification. Examples of suitable in vitro condi-
tions are provided in U.S. Patent Publication No. 2005/ 
0214262; U.S. Patent Publication No. 2006/0030041; and 
U.S. Patent Publication No. 2006/0030041, which are incor-
porated by reference in their entirety. 
Latexin isoforms/variants suitable for antagonist-mediated 
targeting are provided above in [0039] in Subsection I. 
In another embodiment, a HSC population produced by the 
A. Ex Vivo Methods 
Various embodiments provide ex vivo methods for produc-
ing a renewed population ofhematopoietic stem cells (HSCs) 
35 present methods is disclosed, in which the HSCs comprise 
any of the following combination of cell surface markers 
characteristic of HSCs: Thy-1 10 Sea-l+ Lineage- c-kit+; or 
CD150+ CD48- Sea-l+ Lineage- c-kit+; orThy-1 1° CD150+ 
CD48- Sea-l+ Lineage- c-kit+. 
Various embodiments provide methods for reconstituting a 
recipient host with a population of hematopoietic stem cells 
(HSCs) generated ex vivo, in which the method comprises 
obtaining a first HSC population from a donor, contacting the 
first HSC population with an antagonist that reduces latexin 
in which the method comprises obtaining a first HSC popu-
lation from a donor, contacting the first HSC population with 40 
an antagonist that reduces latexin expression and/or latexin 
activity, and culturing the HSC population under in vitro 
conditions that promote cell proliferation and/or inhibit apo-
ptosis to obtain a second HSC population that comprises a 
progeny of the first HSC population. 45 expression and/or latexin activity, culturing the HSC popula-
tion under in vitro conditions that promote cell proliferation 
and/or inhibit apoptosis to obtain a second HSC population 
comprising a progeny of the first HSC population, and pro-
viding the second HSC population to the recipient host in 
The first HSC population and the second HSC population 
can express any of the following combination of cell surface 
markers characteristic of HSCs: Thy-1 10 Sea-l+ Lineage-
c-kit+; or CD150+ CD48- Sea-l+ Lineage- c-kit+; or Thy-1 10 
CD150+ CD48- Sea-l+ Lineage- c-kit+. 50 need ofHSC reconstitution. 
The first HSC population can be obtained from a biopsy 
removed from a donor employing techniques known by per-
sons skilled in the art, including the removal of stem cells 
from the bone marrow of a donor from large bone masses 
utilizing a large needle intended for bone marrow harvesting. 55 
The amount of hematopoietic stem cells needed as the first 
HSC population for the present method is less than the 
amount ofhematopoietic stem cells needed for a conventional 
bone marrow transplantation that may require hundreds of 
needle insertions to obtain sufficient material for direct trans- 60 
plantation into a recipient host. Alternatively, HSCs may be 
collected by apheresis, a process in which a donor's periph-
eral blood is withdrawn through a sterile needle and passed 
through a device that removes white blood cells, and that 
returns the red blood cells to the donor. The peripheral stem 65 
cell yield can be increased with daily subcutaneous injections 
of granulocyte-colony stimulating factor. The HSCs are pref-
The present methods are useful for the treatment of a 
recipient host affected with a disease of the blood, a disease of 
the bone marrow, a cancer of the blood, and a cancer of the 
bone marrow, an immunological disorder, anemia, leukemia, 
thalassemia major, sickle-cell disease, myelodysplastic syn-
drome, lymphoma, aplastic anemia, and/or multiple 
myeloma. Disorders suitable for treatment by the present 
methods include disorders that reduce the number of endog-
enous HSC population, such as genetic disorders that result in 
sub-optimal number of HSCs, cancers that result in sub-
optimal number of HSCs, post-irradiation conditions that 
result in sub-optimal number of HSCs, and post-chemo-
therapy conditions that result in sub-optimal number of 
HSCs. 
The HSC population generated ex vivo by the present 
methods are transferred into a recipient host in need ofHSC 
reconstitution. Such HSC populations that have been exposed 
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to the antagonist, and that have been expanded can be infused 
intravenously into the blood stream of the recipient host. The 
antagonist-exposed and pre-expanded HSC population can 
localize within local niches of a bone marrow after a brief 
circulation in the blood stream. The antagonist-induced and 
pre-expanded HSC population may be able to respond to 
various growth factors produced by endothelial cells within 
the local bone marrow niches that may contribute to further 
proliferation and/or suppression of apoptosis of the antago-
nist-exposed and pre-expanded HSC population. Reconstitu-
tion of HSCs within the recipient host is achieved when the 
total number ofHSCs within the recipient host is at least 25% 
greater than before transplantation of the antagonist-induced 
and pre-expanded HSC population. 
10 
10 
like. For inhalation, suitable formulations containing a phar-
maceutical compound and pharmaceutically-compatible car-
riers can be delivered as aerosol formulations that can be 
placed into pressurized propellants, such as dichlorodifluo-
romethane, propane, nitrogen, and the like. For parenteral 
administration, suitable formulations containing a pharma-
ceutical compound and pharmaceutically-compatible carri-
ers can be delivered by intra-articular, intra-venous, intra-
muscular, intra-dermal, intra-peritoneal, and sub-cutaneous 
routes. 
In one embodiment, the donor is the same organism as the 15 
recipient host in that the donor has identical HLA haplotype 
Pharmaceutical compositions suitable for use include 
compositions containing active ingredients in an effective 
amount to achieve its intended purpose. More specifically, a 
therapeutically-effective amount means an amount effective 
to promote the proliferation ofHSCs and/or inhibit apoptosis 
of HSCs in subjects exposed to the present pharmaceutical as the recipient host, and wherein the recipient host is recon-
stituted with autologous HSCs when provided with the sec-
ond HSC population. For example, allogenic bone marrow 
transplantation involves two persons, a (non-diseased) donor 20 
and a (diseased) patient-recipient. In autologous transplan-
tion, the risks for developing graft rejection, infection, and 
Graft Verses Host Disease ("GVHD") are reduced. 
compositions. Determination of the effective amounts is well 
within the capability of persons skilled in the art. A dose can 
be formulated in animal models to achieve a circulating con-
centration range that includes IC50 value, defined as a dose in 
which 50% of cells of a culture show an effect due to the test 
compound. Such information can be used to more accurately 
determine useful doses in human subjects. In another embodiment, the donor is not the same organism 
as the recipient host, and the donor has a HLA haplotype of 25 
sufficient similarity to the HLA haplotype of the recipient 
host, and wherein the recipient host is reconstituted with 
allogenic HSCs when provided with the second HSC popu-
lation. For optimal results, the allogeneic HSC donors should 
have identical human leukocyte antigens ("HLA") as the 30 
recipient host, and the recipient host should receive immuno-
suppressive medications. For example, an allogenic trans-
plant donor may be a relative (e.g., a sibling) or an unrelated 
volunteer. 
Toxicity and therapeutic efficacy of such compounds can 
be determined by standard pharmaceutical procedures utiliz-
ing cell cultures or experimental animals in order to deter-
mine a LD50 value, the dose determined to be lethal to 50% 
of the exposed population, and to determine a ED 50 value, the 
dose determined to be therapeutically effective in 50% of the 
exposed population. A dose ratio between toxic effect and 
therapeutic effect is referred to as the "therapeutic index," or 
it can be expressed as the ratio of the LD50 value over the 
ED 50 value. Compounds that exhibit high therapeutic indices 
B. In Vivo Methods 
Various embodiments provide methods for reconstituting a 
recipient host with a population of hematopoietic stem cells 
(HSCs) generated in vivo in which the method comprises 
administering to the recipient host a pharmaceutical compo-
sition comprising an antagonist that reduces latexin expres-
sion and/or latexin activity. 
The present methods enable clinicians to promote HSC 
proliferation within the bone marrow of patients affected by 
any type of disorder, disease, or cancer that may reduce the 
supply of endogenous HSCs to less than an optimal number. 
The recipient host is affected with a disease of the blood, a 
disease of the bone marrow, a cancer of the blood, and a 
cancer of the bone marrow, an immunological disorder, ane-
mia, leukemia, thalassemia major, sickle-cell disease, myelo-
dysplastic syndrome, lymphoma, aplastic anemia, and/or 
multiple myeloma. 
The pharmaceutical composition comprises a therapeuti-
cally effective amount of the antagonist. The pharmaceutical 
composition further comprises a pharmaceutical excipient 
known by persons skilled in the art. Pharmaceutical formu-
lations for effective delivery of pharmaceutical composition 
will vary depending on the latexin antagonist and mode of 
administration. Suitable pharmaceutical carriers are known 
by persons skilled in the art (Remington's Pharmaceutical 
Sciences (1989), which is incorporated in entirety). Pharma-
ceutical compositions can be administered by various meth-
ods, including by injection, oral administration, inhalation, 
transdermal application, or rectal administration. For oral 
administration, suitable formulations containing a pharma-
ceutical compound and pharmaceutically-compatible carri-
ers can be delivered in various forms, such as tablets or 
capsules, liquid solutions, suspensions, emulsions, and the 
35 are preferred. The data obtained from cell culture assays and 
animal studies can be used in formulating a range of effective 
dosage for human usage. Optimal dosage range includes a 
ED 50 dose with minimal toxicity, although the dosage may 
vary within this range depending on a given pharmaceutical 
40 formulation and route of administration. Dosage adminis-
tered to a subject should be adjusted according to the age of 
the subject, the weight of the subject, the manner of admin-
istration, and other circumstances unique to each subject. 
C. Exemplary Antagonists that Inhibit the Expression and/or 
45 Activity of Latexin and Latexin I so forms/Variants 
A HSC population obtained from a donor can be induced to 
proliferate ex vivo under in vitro conditions, or an endog-
enous HSC population within a patient can be induced to 
proliferate in situ by exposing the HSC population of interest 
50 to various antagonists that can inhibit latexin gene expression 
and/or latexin activity. 
Suitable compositions that can inhibit the expression and/ 
or the activity of latexin and latexin variants include 
sequence-specific polynucleotides that can interfere with the 
55 transcription of endogenous latexin gene; sequence-specific 
polynucleotides that can interfere with the translation of 
latexin mRNA transcripts (e.g., siRNAs, ribozymes); 
sequence-specific polypeptides that can interfere with the 
protein stability of latexin, the enzymatic activity of latexin, 
60 and/or the binding activity of latexin with respect to sub-
strates and/or regulatory proteins; antibodies that exhibit 
specificity for latexin; and small molecule compounds that 
can interfere with the protein stability of latexin, the enzy-
matic activity oflatexin, and/or the binding activity oflatexin. 
65 An effective antagonist can promote HSC proliferation by at 
least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 
70%,75%, 80%, 85%, 90%,95%, or 100%. 
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1. Sequence-Specific Compounds 
a. RNAi Compounds 
In one embodiment, various siRNAs that are complemen-
tary to human latexin mRNA and mammalian orthologs can 
be employed by persons skilled in the art to promote HSC 
proliferation and/or inhibit HSC apoptosis. By introducing 
such RNAi compounds to a recipient patient deficient in 
HSCs, the silencing or inactivation effect of RNAi com-
pounds on latexin gene/gene products within the HSCs can 
promote HSC proliferation and/or inhibit HSC apoptosis. 
Because introduction of double-stranded RNA ("dsRNA") 
that are longer than 30 nucleotides into mammalian cells 
induces a sequence-nonspecific interferon response, alterna-
tive methods for delivery of interfering RNA molecules 
("RNAi") may be suitable. For example, most common form 
of RNAi molecules are short-interfering RNAs ("siRNAs") 
of 21-23 base-pairs that are chemically or enzymatically syn-
thesized, which can be introduced into mammalian host cells 
by various methods, including transfections. However, unlike 
fungi, plants, and worms that can replicate siRNAs in vivo, 
transfection of siRNA produces only transient gene-silencing 
effect in mammalian cells. As an alternative, DNA vectors 
encoding precursor-like forms of siRNAs may be used for 
stable production of siRNAs in vivo in various hosts, includ-
ing mammalian cells. 
In another embodiment, compounds that can promote HSC 
proliferation and/or inhibit HSC apoptosis are contemplated, 
in which the compounds comprise an oligonucleotide that can 
interact with endogenous messenger RNA encoded by latexin 
gene or by latexin isoforms having at least about 70%, 7 5%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
similarity to SEQ ID NO: 1 (i.e., a sense-strand of human 
latexin eDNA). Such RNA oligonucleotide compounds can 
12 
untranslated regions, such as the" 5'UTR" and "3 'UTR," start-
codons, and exon-exon boundaries. For some mRNA targets, 
siRNA -directed silencing may be more effective if the siRNA 
sequence is selected at least 50-100 nucleotides downstream 
of a start codon, and preferably directed towards the 3' end of 
a target mRNA. In addition, the conformation of a mRNA 
recognition site within an mRNA target is preferably RNAse-
H-sensitive, and preferably not within a highly-structured 
RNA region. These guidelines are generally applicable since 
10 the choice of a siRNA depends on the target mRNA sequence, 
and persons skilled in the art would need to synthesize several 
siRNAs to validate the efficiency of each. The specificity of a 
siRNA for a single gene can be ascertained by performing a 
multiple-genome-sequence alignment, such as a BLAST 
15 search of the selected sequence against sequence databases, 
including "Unigene" libraries associated with National Cen-
ter for Biotechnology Information (NCBI). Potential off-tar-
get silencing by siRNA may be minimized by choosing a 
siRNA sequence with maximum sequence divergence from a 
20 list of genes with partial-sequence identity to the intended 
mRNA target. General principles for siRNA selection are 
taught by the following two review articles, which are incor-
porated by reference (Dorsett and Tuschl, Nature Reviews 
Vol. 3: 318-329, (2004); Dykxhoorn eta!., Nature Reviews 
25 Vol. 4: 457-467 (2003)). 
Various expression vectors can be constructed to enable 
stable production of siRNA-like molecules in vivo. For 
example, RNA-pol II promoters may be operably-linked to a 
hairpin precursor of a siRNA sequence of interest. RNA-pol 
30 II promoters represent a broad range of promoters that enable 
substantial control over parameters governing RNA expres-
sion, such as inducible, constitutive, tissue-specific, or devel-
opmentally-regulated RNA expression. Alternatively, RNA-
pol III promoters may be used to produce short RNA species be single-stranded or double-stranded. Suitable lengths of 
RNA oligonucleotides include molecules containing 15-20 
nucleotides, 20-30 nucleotides, 30-50 nucleotides, 50-75 
nucleotides, 75-100 nucleotides, 100-150 nucleotides, 150-
200 nucleotides, and 200-300 nucleotides. In another 
embodiment, the present invention is directed to compounds 
that can promote HSC proliferation and/or inhibit HSC apo- 40 
ptosis, the compounds include an anti-sense strand that can 
hybridize to an endogenously produced messenger RNA, and 
that can inhibit the translation of the messenger RNA. 
35 that do not activate the interferon pathway. Suitable RNA-pol 
III promoters include class III promoters that lack essential 
transcriptional elements downstream of a transcription initia-
tion site, such as U6 and H1 promoters, which may be oper-
ably-linked to a siRNA-encoding sequence. 
Long-hairpin RNAs, imperfect shRNAs, miRNAs, and 
siRNAs, can be designed as follows. For example, a sub-
sequence of a messenger RNA encoded by latexin gene or by 
latexin isoforms having at least about 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to Selection of efficient siRNAs is an empirical process, but 
certain rules governing optimal selection of siRNAs are 
known. The sequence selected for a siRNA appears to be 
critical. For example, siRNAs containing sequence motifs, 
such as AAN19TT, NAN19NN, NARN17YNN, and 
NANN 17 YNN, are effective, in which N is any nucleotide, R 
is a purine, and Y is a pyrimidine. In addition, regions of 
complementary DNA should have non-repetitive sequences, 
and should avoid intronic sequences. Suitable siRNAs con-
tain approximately 30-70% GC content, contain even repre-
sentation of all nucleotides on the anti-sense strand, and do 
not contain stretches of single nucleotide, especially stretches 
45 SEQ ID N0:1 (i.e., a sense-strand ofhuman latexin eDNA), 
can be targeted. For example, an anti-sense strand of shRNA 
can be designed by selecting a sub-sequence portion of a 
RNA sequence complementary to endogenous latexin mes-
senger RNA and latexin isoforms having at least about 70% 
50 sequence similarity to SEQ ID NO: 1 
For designing shRNA, the composition and size of the loop 
and length of the stem of a hairpin duplex should be consid-
ered. Suitable stem lengths for efficient silencing include a 
broad range, including stem lengths of 19-29 nucleotides. 
55 Suitable loop lengths for efficient silencing include a broad 
range, including loop lengths of 4-23 nucleotides. In certain 
context, hairpin structures with duplexed regions that are 
longer than 21 nucleotides may promote effective siRNA-
of Gs. Designing suitable SiRNA molecules is within the 
scope of persons skilled in the art. The following references 
are herein incorporated by reference in their entirety: Hen-
schel et. a!., Nucleic Acids Research, Vol. 32: 113-120 
(2004); Naito eta!., Nucleic Acids Research, Vol. 32: 124-129 60 
(2004); Dorsett et a!., Vol. 3: 318-329 (2004); and Brum-
melkamp et a!., Nature Reviews, Vol. 3: 781-789 (2003); 
Pusch eta!., Nucleic Acid Research, 31: 6444-6449 (2003); 
and Chiu eta!., RNA 9: 1034-1048 (2003). 
directed silencing, regardless ofloop sequence and length. 
Various gene-delivery vectors that are practiced by persons 
skilled in the art can be used to introduce the present expres-
sion vectors. Examples of viral vectors that may be used to 
infect HSC cells include: improved adenoviral vectors (Rey-
nold eta!., Nature Biotechnology 19: 838-842 (2001 )); gene-
Although any region of mRNA can be theoretically tar-
geted, certain sequences that are known binding sites for 
mRNA-binding proteins should be avoided, including 
65 deleted adenovirus-transposon vectors (Yant et a!., Nature 
Biotechnology 20: 999-1005 (2002)); recombinant adenovi-
ruses (Bilang-Bleuel eta!., Proc. Nat!. Acad. Sci. U.S.A. 94: 
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8818-8823 (1997)); the Moloney-murine-leukemia-virus 
("Mo-MuLV") based retroviral vectors (Auten eta!., Human 
Gene Therapy 10: 1389-99 (2003)); and poliovirus-replicon-
based vectors (Bledsoe eta!., Nature Biotechnology 18: 964-
969 (2000)). Examples of other suitable viral vectors include: 5 
herpes virus, mumps virus, Sindbis virus, vaccinia virus, such 
as the canary pox virus, and lentivirus. The usage of viral 
vectors is well known by persons skilled in the art, and for 
gene therapy uses, viral infection is preferred generally. The 
following references are incorporated by reference in their 10 
entirety: Rob bins and Ghizzani, Mol. Med. Today 1:41 0-41 7 
(1995); Robin eta!., Stem Cells 20:514-521 (2002); Chen et 
a!., Immunity 19:525-533 (2003); North eta!., Immunity 16: 
661-672 (2002); Zhou eta!., Nature Medicine 7: 1028-1034 
(2001 ); Ivanova eta!., 298: 601-604 (2002); and Santos et. a!., 15 
Science 298: 597-600 (2002). 
b. Chemically Modified Anti-Sense Oligodeoxyribonucleic 
Acids ("ODNs") 
In one embodiment, various oligodeoxyribonucleic acid 
(ODN) molecules that are complementary to endogenous 20 
messenger RNA encoded by latexin gene or by latexin iso-
formshavingatleastabout70%, 75%,80%,85%,90%,95%, 
96%, 97%, 98%, or 99% sequence similarity to SEQ ID NO: 1 
(i.e., a sense-strand of human latexin eDNA), can be 
employed by persons skilled in the art to promote HSC pro- 25 
liferation and/or to inhibit HSC apoptosis. By introducing 
such oligodeoxyribonucleic acid (ODN) molecules to a 
recipient patient deficient in HSCs, the silencing or inactiva-
tion effect of RNAi compounds on latexin gene/gene prod-
ucts within the HSCs can promote HSC proliferation and/or 30 
inhibit HSC apoptosis. Suitable oligodeoxyribonucleic acid 
molecules ("ODNs") are short polynucleotides of approxi-
mately 20 nucleotides in length, that can hybridize with pre-
mRNA and mRNA to form RNA-DNA duplexes, which are 
degraded by ribonuclease H ("RNase H"). Such ODNs can be 35 
chemically modified to prevent the action of RNase H, to 
inhibit translation of mRNA by steric hindrance, to inhibit 
splicing of pre-mRNAs, and to inhibit transcription by the 
formation of triple helices. Kurreck, J. eta!., Eur. J. Biochem., 
270:1628-1644 (2003); Baker et a!., J. Bioi. Chern., 272: 40 
11994-2000 (1997); Lu, Q. L. eta!, Nature Med., 9:1009-
1014 (2003); and Uil, eta!., Nucleic Acids Res., 31:6064-
6078 (2003) are incorporated by reference in their entirety. 
c. Ribozymes 
In one embodiment, various ribozymes containing 45 
sequences that are complementary to endogenous messenger 
RNA encoded by latexin gene or by latexin isoforms having at 
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 
98%, or 99% sequence similarity to SEQ ID NO: 1 (i.e., a 
sense-strand of human latexin eDNA), can be employed by 50 
persons skilled in the art in order to reduce latexin expression 
and/or latexin activity that results in HSC proliferation and/or 
HSC apoptosis. Ribozymes, including the "hammer-head" 
ribozyme, are RNA molecules that bind target mRNA by 
assuming a unique secondary structure when hybridized to 55 
target mRNA, which enables catalytic hydrolysis of a phos-
phodiester bond within in the backbone of target mRNA. 
Efficient cleavage by a ribozyme requires the presence of 
divalent ions, such as magnesium, and is also dependent on 
target RNA structure, and relative proximity between 60 
ribozyme and target molecule. RNA-localization signals or 
RNA chaperones may be used so that low concentrations of 
ribozymes are sufficiently effective in silencing latexin and 
latexin isoforms. Ribozymes can be chemically synthesized 
in vitro, and can be transcribed from expression vectors in 65 
vivo. Methods for ribozyme construction and utilization are 
known by persons skilled in the art. Doudna and Cech, 
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Nature, 418:222-228 (2002); Kuwahara eta!, J. Biochem., 
132:149-155 (2002); Michienzi and Rossi, Methods Enzy-
mol., 341:581-596 (2001); and Good eta!., Gene Ther. 4:45-
54, (1997) are herein incorporated by reference. 
d. Other Compounds 
In another embodiment, suitable antagonists include com-
pounds that can interact with polypeptides having at least 
about70%, 75%,80%,85%,90%,95%,96%,97%, 98%,or 
99% sequence similarity to SEQ ID N0:2, that can inhibit the 
activity of the bound polypeptide, and that can promote the 
proliferation ofHSCs and/or suppress the apoptosis ofHSCs. 
In addition, compounds that can interact with genomic DNA 
containing exons having at least about 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to 
SEQ ID N0:1 (i.e., a sense-strand of human latexin eDNA) 
can be employed. In addition, compounds that can interact 
with RNA transcripts encoded by a gene, in which the exon 
sequences have at least about 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, or 99% sequence similarity to SEQ ID 
N0:1 (i.e., a sense-strand of human latexin eDNA) can be 
employed. Various compounds that can inhibit the expression 
and/or activity of latexin or latexin isoforms can be either 
naturally-occurring or synthetically-produced. Large combi-
natorial libraries of chemical/biological compounds can be 
generated by various chemical and biological synthesis meth-
ods known in the art. Such combinatorial chemical libraries 
include: small organic molecule libraries (benzodiazepines, 
Baum C&EN, Jan. 18, page 33 (1993)); Chen eta!., J. Amer. 
Chern. Soc. 116:2661 (1994)), such as isoprenoids (U.S. Pat. 
No. 5,569,588), thiazolidinones and metathiazanones (U.S. 
Pat. No. 5,549,974), pyrrolidines (U.S. Pat. Nos. 5,525,735 
and5,519,134),morpholino compounds (U.S. Pat. No. 5,506, 
337), and benzodiazepines (U.S. Pat. No. 5,288,514), oligo-
carbamates (Cho eta!., Science 261:1303 (1993)), and pep-
tidy! phosphonates (Campbell et a!., J. Org. Chern. 59:658 
(1994)). Exemplary combinatorial libraries include: various 
peptide libraries (U.S. Pat. No. 5,010,175; Furka, Int. J. Pept. 
Prot. Res. 37:487-493 (1991); Houghton eta!., Nature 354: 
84-88 (1991)); peptoid libraries (PCT Publication No. WO 
91/19735); encoded peptides (PCT Publication No. WO 
93/20242); random bio-oligomers (PCT Publication No. WO 
92/00091); benzodiazepines (U.S. Pat. No. 5,288,514); diver-
somers such as hydantoins, benzodiazepines and dipeptides 
(Hobbs et a!., Proc. Nat. Acad. Sci. USA 90:6909-6913 
(1993)); vinylogous polypeptides (Hagihara eta!., J. Amer. 
Chern. Soc. 114:6568 (1992)); nonpeptidal peptidomimetics 
with glucose scaffolding (Hirschmann eta!., J. Amer. Chern. 
Soc. 114:9217-9218 (1992)); various nucleic-acid libraries; 
various peptide-nucleic acid libraries (U.S. Pat. No. 5,539, 
083); various carbohydrate libraries (Liang et a!., Science, 
274:1520-1522 (1996); U.S. Pat. No. 5,593,853)); and vari-
ous antibody libraries (Vaughn eta!., Nature Biotechnology, 
14(3):309-314 (1996)). 
D. Identification ofFunctionally-Related Isoforms ofLatexin 
The present methods and compositions can be employed 
for targeting variants of latexin that have similar properties/ 
activities within HSCs of many types of mammalian subjects. 
Functionally-related isoforms oflatexin can be identified by 
searching various genomic databases and conducting multi-
genome-wide sequence alignments in order to identifY 
homologous sequences of interest. Related orthologous 
sequences can be identified by searching composite genomic 
databases. The breath of a database search is limited by the 
scope of representative model organisms for which sequence 
data is available. 
Homology can be determined by various methods, includ-
ing alignments of open-reading-frames ("ORFs") contained 
in private and/or public databases.Any suitable mathematical 
algorithm may be used to determine percent identities and 
percent similarities between any two sequences being com-
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pared. For example, nucleic acid and protein sequences of the 
present invention can be used as a "query sequence" to per-
form a search against sequences deposited within various 
public databases to identify other family members or evolu-
tionarily-related sequences. Genomic sequences for various 
organisms are currently available, including fungi, such as the 
budding yeast, or Saccharomyces cerevisiae; invertebrates, 
such as Caenorhabditis elegans and Drosophila melangaster; 
and mammals, such as the mouse, rat, and human. Exemplary 
databases for identifYing orthologs of interest include 
Genebank, Swiss Protein, EMBL, and National Center for 
Biotechnology Information ("NCBI"), and many others 
known in the art. These databases enable a user to set various 
parameters for a hypothetical search according to the user's 
preference, or to utilize default settings. Tables 1-3, provided 
below, lists the accession numbers and gene identification 
numbers for exemplary mammalian orthologs. Suitable 
latexin variant that may be targeted for suppression or inhi-
bition include the carboxypeptidase inhibitor (CARIN) 
described in U.S. Pat. No. 5,998,373. 
TABLE 1 
Gene Bank Accession Number for Exemplary Mouse, 
Human and Rat Latexin mRNA. 
Organism 
Mus musulus 
(Mouse) 
Accession Number 
NM-016753 
Gene IDS 
31980631 
Organism 
10 
15 
20 
25 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
Mus musulus 
(Mouse) 
16 
TABLE !-continued 
Gene Bank Accession Nwnber for Exemplary Mouse, 
Human, and Rat Latexin mRNA. 
Organism Accession Number Gene IDS 
Rattus norvegicus NM-031655 14269567 
(Rat) 
Homo Sapiens NM-020169 21359932 
(human) 
TABLE2 
Gene Bank Accession Nwnber for Exemplary Mouse, 
Hwnan and Rat Latexin Protein. 
Organism Accession Number Gene IDS 
Mus musulus NP-058033 31980632 
(Mouse) 
Rattus norvegicus NP-113843 14269568 
(Rat) 
Homo Sapiens NP-064554 21359933 
(human) 
TABLE3 
Accession 
Number 
AK032170.1 
AK149981.1 
D88769.1 
AC124190.4 
AC124190.4 
AC124190.4 
AC124190.4 
AC124190.4 
AC124190.4 
AK018305.1 
Mammalian Homologs for Latexin 
Percentage 
Gene IDS Identity Gene Information 
26327996 99.91 Mus musculus adult 
male olfactory brain 
eDNA, RIKEN full-
length enriched library, 
clone: 6430407E02 
product: Latexin, full 
insert sequence 
74211713 100.00 Mus musculus bone 
marrow macrophage 
eDNA, RIKEN full-
length enriched library, 
clone: G530111019 
product: Latexin, full 
insert sequence 
1669620 99.50 Mus musculus mRNA 
for Latexin, complete 
cds 
23499687 100.00 Mus musculus BAC 
clone RP23-267M9 
23499687 100.00 from 3, complete 
sequence 
23499687 100.00 
23499687 100.00 
23499687 100.00 
23499687 100.00 
12857946 99.58 Mus musculus 10 days 
neonate cerebellum 
eDNA, RIKEN full-
length enriched library, 
clone: 6530401A10 
product: Latexin, full 
insert sequence 
US 9,284,530 B2 
Organism 
Mus musulus 
(Mouse) 
Accession 
Number 
AK198791.1 
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TABLE 3-continued 
Mammalian Homologs for Latexin 
Percentage 
Gene IDS Identity Gene Information 
56022968 100.00 Mus musculus eDNA, 
clone: Y1 G0129D08, 
strand: minus, 
reference: ENSEMBL: 
Mouse-Transcript-
ENST: ENSMUST00000058981, 
based on 
BLAT search 
Mus musulus AK187030.1 56011207 99.52 Mus musculus eDNA, 
(Mouse) clone: YOG0139J09, 
strand: minus, 
reference: ENSEMBL: 
Mouse-Transcript-
ENST: ENSMUST00000058981, 
Rattus Y18435.2 6066618 94.33 
norvegicus 
(Rat) 
Rattus Y18435.2 6066618 96.92 
norvegicus 
(Rat) 
EXAMPLES 
based on 
BLAT search 
Rattus norvegicus 
Latexin gene, exons 1 
to 6 
age is indicated with the dashed bar. Data were analyzed by 
either student t-test by assuming unequal variance with 
p<0.05 (two-tail or one-tail as indicated), or by one-way The following examples are offered by way of illustration 
and not by way of limitation. Examples 1 provides a map of 
congenic intervals defined in the reciprocal strains. Example 
30 ANOVA. 
2 provides an in vitro method for determining HSC frequen-
cies by cobblestone area-forming cell (CAFC) assay. 
Example 3 provides an in vivo method for determining HSC 
frequencies by a competitive limiting-dilution assay. 35 
Example 4 provides the identification oflatexin by a genome-
wide linkage analysis that correlates three QTL with HSC 
population size. Example 5 provides data that validates the 
linkage analysis and heritability of latexin. Example 6 pro-
vides the effect of latexin on HSC Replication. Example 7 40 
provides the effect oflatexin on HSC Self-renewal. Example 
8 provides the effect of latexin expression on apoptosis. 
Example 9 provides microarray analysis of LSK cells. 
Example 10 provides Lxn mRNA levels in hematopoietic 
cells. Example 11 provides Lxn expression in undifferenti- 45 
ated and differentiated hematopoietic cell populations. 
Example 12 provides Lxn protein levels in hematopoietic 
cells of congenic and background strain mice. Example 13 
provides Cis-Regulation ofLxn expression. Example 14 pro-
vides a decrease in stem cell numbers by the overexpression so 
ofLxn. 
Example 1 
The Chr 3 congenic mice were generated by well-estab-
lished methods known in the art. Mouse strains congenic for 
the Chr 3 QTL were generated by crossing the genomic 
interval harboring the QTL using D2, as the donor strain, and 
B6, as the recipient strain (symbolized as B.D Chr3), and vice 
versa (D.B Chr3). The two reciprocal congenic strains were 
derived by a 'speed congenic' approach involving at least 
eight backcrosses with the respective background strains. 
Both congenic lines were homozygous within their respective 
congenic intervals and genotyped exclusively for background 
strain alleles using 100 microsatellite markers scattered 
throughout the non-congenic genome. Congenic mice were 
genotyped every 6 months through genetic marker-based 
polymerase chain reaction. All primers for simple sequence 
repeat (SSR) element markers were bought from Research 
Genetics (Huntsville, Ala.). Two strains of Chr 3 congenic 
mice were generated and maintained: B.D Chr3 (14 cM-33 
eM) congenics with D2 QTL being introgressed onto the B6 
background, and their reciprocal congenic strains D.B Chr3 
(19 cM-60 eM) with B6 QTL on a D2 background. B6.SJL 
(Ptprc6 [CD 45.1]) mice from Charles River laboratories (Fre-
derick, Md.) were used as transplantation recipients in com-
petitive repopulation experiments. Female mice (6 to 10 
weeks old) were housed in the animal facilities of the Uni-
Mapping Congenic Intervals Containing Latexin 55 versity of Kentucky under pathogen-free conditions accord-
ing to NIH-mandated guidelines for animal welfare. They 
were fed with acidified water and food ad libitum. FIG. 2 illustrates a genomic map of congenic intervals 
identified in reciprocal Chr.3 congenic mouse strains. The 
congenic interval, mutually inclusive in the two reciprocal 
strains, spans from 36.5 megabase (Mb) (19.2 centiMogan 60 
(eM)) to 67 Mb (33 eM), and the location of the marker 
(D3Mit5) most tightly linked to the trait is localized within 
50.4 Mb (25 eM). The C57BL/6 ("B6") (Ptprc6 [CD 45.2]) 
and DBA/2 ("D2") mice were background strains and pur-
chased from the Jackson Laboratories (Bar Harbor, Me.). The 65 
total length of Chr3 (-160 Mb) is indicated on the top. 
Genomic interval with 95% of confidence limits of the link-
Example 2 
Determination of HSC Frequencies by In Vitro 
Cobblestone Area-Forming Cell (CAFC) Assay 
To quantifY primitive hematopoietic cells derived from 
bone marrow in B6, D2, and 26 BXD RI strains, an in vitro 
cobblestone area-forming cell (CAFC) assay was performed. 
In this assay, each cobblestone area represents a population 
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formed by clonal amplification of a single stem cell or a 
progenitor cell, and distinct populations arise in a chronologi-
cal continuum. For determining the relative chronological 
age of a hematopoietic cell, the latency period is determined 
20 
by hypotonic lysis using NH4 Cl. The leukocytes were stained 
in triplicate with fluorescein isothiocyanate (FITC)-conju-
gated anti-CD45.2 monoclonal antibody (mAb) (clone 
ALI4A2) and phycoerythrin (PE)-conjugatedmAbs (Becton-
Dickinson-PharMingen, San Diego, Calif.) specific for either 
B (anti-CD45R/B220; clone RA3-6B2) or T lymphocytes 
(anti-Thy-1.2; clone 30H12), or granulocytes (anti-Ly6G/Gr-
1; clone RB6-8C5), and macrophages (anti-CD11 b/Mac-1; 
clone M1/70). Samples were analyzed using a FACScan 
by measuring the duration before clonal expansion by a 5 
primitive hematopoietic cell. A longer latency period indi-
cates a more primitive hematopoietic cell. Cobblestone areas 
were counted after 35 days of culture, a late time-point. Primi-
tive hematopoietic cells measured at this time-point correlate 
strongly with long-term repopulating stem cells in vivo. 
Whole bone marrow cells and sorted LSK cells, described 
below in Example 5 and FIGS. 4A-4B, were evaluated in a 
cobblestone area-forming cell (CAFC) assay. In brief, a con-
fluent monolayer ofFBMD-1 stromal cells was established in 
96-well tissue culture-treated plates (Costar, Cambridge, 15 
Mass.). After 7 to 10 days, wells were seeded either with 
unfractionated marrow at a dose of 81,000, 27,000, 9,000, 
3,000, 1 ,000, or 333 cells per well, or with sorted LSK cells at 
10 instrument (Becton-Dickinson Immunocytometry Systems, 
San Jose, Calif.). The frequencies of long-term HSCs were 
calculated from the proportions of negative recipients in each 
cell dose group by using L-Calc software (StemCell Tech-
a dose ofl, 3, 10, or 30 cells per well using an automated cell 
deposition unit. Twenty or 60 replicate wells per cell number 20 
were evaluated in experiments with unfractioned or sorted 
cells, respectively. The cells were cultured in Iscove's Modi-
fied Dulbecco Medium (IMDM), containing 20% horse 
serum, 80 U/mL penicillin, 80 mg/mL streptomycin (all from 
Life Technologies), 10-4 ~-mecaptoethanol, and 10-5 M 25 
hydrocortisone (both Sigma, St. Louis, Mo.). Individual wells 
were screened at day 7, 14, 21, 28 and 35 for the presence of 
a cobblestone area, defined as a colony of at least 5 small, 
non-refractile cells growing underneath the stroma. A longer 
latency period before the appearance of cobblestones corre- 30 
lates with a more primitive state of the stem cell. Thus, the 
most primitive HSCs show cobblestones at day 35, whereas 
colonies that appear earlier are derived from more committed 
progenitor cells (HPCs ). Frequencies of CAFCs were calcu-
lated by using maximum likelihood analysis and are equal to 35 
1 divided by the number of cells yielding 3 7% negative wells. 
The frequencies of CAFC day35 in BXD RI mouse strains 
were measured, and were used to perform genome-wide 
searches for linked loci within a GeneNetwork database. 
nologies Inc., Vancouver, BC). In each cell dose group, <5% 
of the circulating B, T, and myeloid cells were regenerated 
from CD45.2 stem cells. The results obtained from two inde-
pendent experiments showing the effect of D2 alleles on the 
number of long-term repopulating HSCs in B.D Chr3 mice 
are provided below in FIG. 4C in Example 5. 
Example 4 
Identification of Latexin by Linkage Analysis 
FIG. 3 illustrates a genome-wide linkage analysis based on 
GeneNetwork that associates the trait regulating HSC popu-
lation size with three quantitative trait loci (QTL) on Chro-
mosomes (Chr) 3, 5, and 18, respectively. In FIG. 3, these 
QTLs linked genetically to the trait ofHSC population regu-
lation at a 'suggestive' statistical level of association, in which 
the likelihood ratio statistic (LRS) values (solid blue line) for 
the corresponding markers (D3Mit5, D5Mit352, D18Mit53) 
are located between the suggestive threshold (dashed green 
line) and the significant threshold (dashed blue line). The 19 
autosomes and Chr X of the mouse genome are labeled across 
the top, and some of micro satellite markers are listed across 
the bottom. The positive additive regression coefficient (solid 
red line) for each QTL indicates that D2 alleles increase the 
trait and that the B6 alleles decrease the trait. The positive 
Example 3 
40 additive regression coefficient for each QTL indicates that the 
D2 alleles have a positive effect on HSC population size and 
that the B6 alleles have a negative effect on HSC population 
In Vivo Determination of HSC Frequencies in 
Rodents by Competitive Limiting-Dilution Assay 
A limiting-dilution analysis in competitively repopulated 
host animals was performed over a long term (20 week) 
period in order to functionally identifY and to quantifY HSCs 
45 
SIZe. 
Example 5 
Validation of the Linkage Analysis and Heritability 
ofLatexin 
To validate the results from genome-wide linkage analysis 
described in Example 4, CAFC day 35 assays were performed 
on whole bone marrow cells and LSK cells. FIG. 4A illus-
trates the CAFC day 35 frequency observed for femur cells 
(whole bone marrow cells derived from reciprocal congenic 
in vivo. Graded numbers ofbone marrow cells from B.D Chr3 
congenic or B6 mice were first admixed with a fixed dose of 50 
competitor cells, and were transplanted into groups of 
lethally-irradiated mice. Lymphomyeloid reconstitution by 
either B.D Chr3 or B6-derived cells was assessed in the 
peripheral blood cells 20 weeks after transplantation. In lim-
iting-dilution competitive repopulation assay, graded num-
bers (6,000; 20,000; and 60,000) ofB.D Chr3 congenic or B6 
"test" cells (CD45.2) were admixed with a radio-protective 
dose (2x105 ) of competitor cells (CD45.1), and were injected 
intravenously into lethally irradiated (900 Gy) CD45 .1 recipi-
entmice. 
55 strains) of Chr3 congenic mice when compared to back-
ground mice. In FIG. 4A, introgression ofD2 alleles onto the 
B6 background in the QTL region caused nearly a 2-fold 
increase in CAFC day35 number (P=0.003) representing the 
number of HSCs in B.D Chr3 congenic mice, whereas the 
60 introgression of B6 alleles onto the D2 background caused 
more than a 50% decrease (P=0.02). The values are shown as 
mean±SEM (n>9). The absolute number of CAFC day35 per 
femur (±SEM) for all strains as follows: B66: 397±59; B.D 
Chr3: 724±73; D2: 1978±684; D.B Chr3; 1532±286. More-
Recipients were bled from the retro-orbital sinus 20 weeks 
after transplantation. Peripheral blood cell counts were per-
formed on anesthetized mice bled from the retro-orbital 
venous plexus. Circulating leukocyte, erythrocyte, and plate-
let counts were measured by analysis of 40 ul blood using a 
System 9118+ Hematology Series Cell Counter (Biochem 
Immunosystems, Allentown, Pa. Erythrocytes were depleted 
65 over, numbers for CAFC day 7 and day 21, which represent 
hematopoietic progenitor cells (HPCs) at different stages, and 
the cell counts for peripheral blood leukocytes, erythrocytes, 
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and platelets showed no differences among congenic and 
background strains. This suggested that the Chr 3 QTL spe-
cifically regulates HSC population size. 
FIG. 4B illustrates the CAFC day 35 frequency observed 
for LSK cells of Chr3 congenic mice compared to back- 5 
ground mice. The LSK cells represent a highly-enriched 
population ofHSCs comprising about 0.03% of total marrow. 
In FIG. 4B, similar to results obtained with unfractionated 
marrow in FIG. 4A, the D2 alleles significantly increased the 
CAFC day35 number when compared to B6 alleles exhibiting 
10 
a decreased CAFC day35 number in the LSK population 
(P<0.05). The values are shown as mean±SEM (n>9). The 
absolute number of CAFC day35 per 100,000 Lin-negative, 
Sea-l+, c-kit+ cells (±SEM) for all strains as follows: 
B6:1316±172; B.D Chr3: 2000±218; D2: 10000±1010; D.B 
Chr3; 7143±721. The LSK cells, were isolated by selecting a 15 
bone marrow population null for cell markers characteristic 
22 
approaches. First, in vivo BrdU incorporation was used to 
determine cells in the S phase of the cell cycle. Mice were 
injected intraperitoneally with BrdU (1 mg per kg body 
weight) and sacrificed 90 minutes later. Bone marrow LSK 
cells were identified as described above. Analysis of BrdU 
incorporation in LSK was performed using BrdU Flow Kit 
(Pharmingen, San Diego, Calif.) according to the manufac-
turer's instruction. Second, the fraction of cells killed by a 
1-hour in vitro incubation with hydroxyurea (HU) was mea-
sured. Hydroxyurea (HU) is an agent that blocks DNA syn-
thesis and stops cell division by inhibiting ribonucleotide 
reductase. Briefly, all bone marrow cell suspensions were 
diluted to a concentration of lxl07 cells in 1 mL. Hydrox-
yurea (Sigma, StLouis, Mo.; 200 ug/mL, a total volume of 10 
ul) was added to one sample, and incubated with the control 
sample for 1 hour at 33° C. The standard CAFC assay was 
then used to assay both HU-treated and control samples. The 
fraction of cells killed by HU was calculated by dividing the 
of lineage-specific differentiated blood cells (Lin-negative) 
and positive for the Sea-l and c-Kit cell markers. This popu-
lation was sorted using flow cytometry and assayed for CAFC 
day 35 numbers in 4 strains. 
FIG. 4C illustrates the effect ofD2 alleles on the number of 
long-term repopulating HSCs in B.D Chr3 mice. In FIG. 4C, 
20 CAFC frequency in the HU-treated sample by the control 
value. 
D2 alleles that introgressed in the region of the Chr 3 QTL 
caused a 73% increase in the total number of long-term 
repopulating HSCs (P=0.04) in B.D Chr3 mice compared to 25 
B6 mice, as determined from two independent experiments. 
Total number of long-term repopulating HSCs (LTRC) B.D 
Chr3 congenic and B6 mice is shown, as average per femur 
(±SEM). LTRC frequencies were measured by competitive 
limiting-dilution analysis described below using femur cells 
30 ofB6 and B.D Chr3 mice. Thus, both qualitatively and quan-
titatively, these results corroborated the results obtained in 
vitro. 
A long-term, limiting-dilution analysis in competitively 
repopulated animal hosts was performed, as further described 
above in Example 3. Graded numbers of bone marrow cells 35 
from B.D Chr3 congenic or B6 mice were admixed with a 
fixed dose (2xl 05 ) of competitor cells and transplanted into 
groups of lethally-irradiated mice irradiated to ablate their 
endogenous hematopoietic system. The competitor cells and 
recipient mice have a CD45.1 surface marker, whereas B.D 40 
Chr3 and B6 mice carry the CD45.2 marker on virtually all 
hematopoietic cells. This genetic marker is not presently 
available on the D2 background that also bears CD45.2, 
which precludes analogous experiments with the reciprocal 
congenic strain. Twenty weeks after transplantation, lympho- 45 
myeloid reconstitution by either B.D Chr3 or B6-derived 
cells was assessed in the peripheral blood cells 20 weeks after 
transplantation for the presence of CD45.2 cells by flow 
cytometry. 
Together, these three independent studies support the con- 50 
elusion that a Chr 3 QTL in the congenic intervals confers the 
phenotype (HSC population regulation), and confirms the 
results obtained by linkage analysis. In the context of these 
congenics, the QTL accounts for a significant portion of the 
natural variation of this parameter between the progenitor 55 
strains, despite 'suggestive' linkage of the phenotype with 
two other QTLs (Chr 5 and ChriS) and with the presence of 
several other QTLs that approach 'suggestive' linkage illus-
trated in FIG. 3. 
FIG. SA illustrates that D2 alleles confer an increase in 
HSC replication and that B6 alleles confer a decrease in HSC 
replication. The role of Chr 3 QTL in HSC replication, the 
proportion of LSK cells in S phase of the cell cycle were 
determined by measuring the incorporation of 5-bromodeox-
yuridine (BrdU). In agreement with previous data, 4.5% 
(± 1.7%) ofB6 LSK cells were labeled with BrdU for one hour 
following administration in vivo, whereas more than twice as 
many D2 LSK cells were labeled under the same conditions 
(11%±2.5%) (P=O.Ol). In FIG. SA, introgressionofD2 alle-
les significantly increased the BrdU-positive LSK population 
(15%±1.4%) (P=O.OOOl) in B.D Chr3 congenic LSK cells, a 
proportion similar to that found in D2 cells. As expected, B6 
alleles decreased the BrdU incorporation and conferred the 
B6 phenotype to D.B Chr3 cells (5.9%±1.2% ). Replication of 
HSCs measured by BrdU incorporation in animals given a 
single pulse ofBrdU. Results present the mean (±1 SD) of the 
fraction ofBrdU positive LSK cells (n=S per strain).* indi-
cates the comparison between B6 and D2, and ** indicates 
the comparison between congenics and their respective back-
ground mice. P values are shown in the figure. 
To determine the effect of QTL on cell cycle kinetics, the 
CAFC day7 progenitor cells killed by hydroxyurea (HU) in 
the reciprocal congenic strains, B6, and D2 mice were mea-
sured. FIG. SB illustrates the effect of Chr 3 QTL on the 
cell-cycle kinetics of the progeny ofHSCs, also referred to as 
hematopoietic progenitor cells (HPCs). Proliferation of 
HPCs measured by CAFC day7 cells killed by hydroxyurea 
(HU) in reciprocal congenic and B6, D2 strains. Data are 
shown as the average (±SD) of 3 independent experiments 
(n;;:9). *indicates the comparison between B6 and D2, and** 
indicates the comparison between congenics and their respec-
tive background mice. P values are shown in the figure. The 
results showed that the D2 alleles in and around the Chr 3 
QTL in a B6 background quantitatively can reproduce the 
higher killing rate observed in D2 mice. Similarly, B6 alleles 
on a D2 background reproduced the entire variation in this 
Example 6 
The Effect of Latexin Expression on HSC 
Replication 
60 trait between B6 and D2 mice. These results underscore the 
effect of the Chr 3 QTL on cell-cycle kinetics of HSC and 
their immediate progeny. Interestingly, progenitor cell num-
bers and differential blood cell counts showed no differences 
among the congenic and background strains, showing that 
The effect oflatexin expression on the proliferative activity 
of various primitive cells was assessed using two independent 
65 compensatory mechanisms during downstream amplification 
of differentiating cells obviated the variation in the final cell 
outputs in the multiple blood cell lineages. 
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Example 7 
The Effect of Latexin Expression on HSC 
Self-Renewal 
24 
the comparison between B6 and D2, and ** indicates the 
comparison between congenics and their respective back-
ground mice. P values are shown in the figure. 
Introgression of D2 alleles around the Chr 3 QTL, in the 
5 B.D Chr3 congenic, resulted in an apoptotic LSK subpopu-
lation (0.6%±0.1 %) similar to that of D2 mice, which sug-
gests that the congenic interval conferred the entire pheno-
type. Surprisingly, analysis of marrow from the reciprocal 
congenic strain revealed a very low (0.3%±0.03%) apoptotic 
The self-renewal capacity ofB.D Chr3 congenic HSCs was 
tested in serial transplant experiments in which B.D Chr3 
congenic HSCs and B6 marrow cells were co-transferred to 
recipients so that both types of cells competed for engraft-
ment. In serial bone marrow transplantation, B.D Chr3 con-
genic or B6 "test" cells were injected into the primary recipi-
ents along with equal number of competitor cells (lxl06 ). 
Sixteen weeks after transplant, marrows were harvested from 
the primary recipients, and were transplanted into secondary 
recipients. An identical regimen was repeated twice more, 
culminating in engrafted quaternary hosts. At each transplant, 
the peripheral blood, bone marrow, and bone marrow LSK 
cells were analyzed. The competitive advantage and self-
renewal capacities were analyzed by comparing the percent-
age ofB.D Chr3 congenic-derived or B6-derived cells at each 20 
round of transplantation. 
10 LSK population. Thus, B6 alleles at and around the QTL do 
not confer the B6 phenotype onto D2 HSCs. In fact, apoptosis 
was significantly (P=0.02) less than in the D2 background 
strain. This result may be due to genes in the mutually exclu-
sive congenic intervals of the reciprocal strains, or genes in 
15 the D2 background having a strong negative effect on HSC 
apoptosis. The results suggest that the QTL might act through 
a mechanism influencing apoptosis in HSCs. 
Example 9 
FIG. SC illustrates that D2 alleles of the Chr 3 QTL confer 
HSCs with higher self-renewal capability. In FIG. SC, con-
genic stem cells maintained their competitive advantage at 
every round of transplantation in each cell population, dem- 25 
onstrating that they retained the characteristic ability of stem 
cells to self-renew and to give rise to normal differentiated 
progeny when challenged with replicative stress. Consistent 
with the extensive self-renewal ability ofB.D Chr3 stem cells, 
Microarray Analysis of LSK Cells to IdentifY 
Differentially Expressed genes within Consenses 
Congenic Interval 
Oligonucleotide arrays ofLSK cells were performed by the 
Microarray Facility Center at the University of Kentucky. 
Briefly, total RNA were extracted from at least 550,000 sorted 
LSK cells from a minimum of 40 mice using RNeasy® Kit 
(QIAGEN, Valencia, Calif.). The extracted RNA was reverse 
transcribed into eDNA, which was subsequently used to syn-
thesize biotin-labeled cRNA. The labeled cRNA was then 
all (16) of the quaternary recipients transplanted with con- 30 
genic cells survived long-term, whereas half (8 of 16) of the 
recipients receiving only B6 cells failed to survive to the 
10-week evaluation time-point in 4'h generation recipients. 
Thus, serial bone marrow transplantation in a competitive 
repopulation setting clearly demonstrates that D2 Chr 3 QTL 35 
confers HSCs with higher self-renewal capability, and that 
this capacity is intrinsic to the HSCs. B.D Chr3 (dashed line) 
fragmented and hybridized to the Mouse Genome U74Av2 
chips (MGUAv2, Aff)'metrix, Santa Clara, Calif.). The gene-
chips were then washed, stained, and subsequently scam1ed 
for quantification of gene expression. Three independent bio-
logical samples were obtained for each strain and each was 
run on an individual chip. The gene expression levels were 
compared among all4 strains using one way-ANOVA with a 
statistical cutoff ofP<0.05. The genes that were differentially 
expressed were screened for genomic location and function 
of the gene products. 
Oligonucleotide arrays were utilized to screen for genes in 
the consensus congenic interval whose differential expres-
sion may account for the observed phenotypic variations. 
or B6-derived (solid line) peripheral blood leukocytes, BM 
nucleated and BM LSK cells were analyzed 16 weeks after 
they were transplanted into primary (1st), secondary (2nd), 40 
tertiary (3rd) and quaternary (4th) recipients. Each data point 
represents the average for groups of mice (n2:l6). The sur-
vival rate of quaternary recipients transplanted with either 
B.D Chr3 or B6 cells is shown in the last panel. 
45 LSK cells were sorted from bone marrow of the reciprocal 
congenic mice, and the two background strains mice. Large 
independently sorted biological samples for total RNA 
extraction were used to avoid representational skewing oflow 
abundance mRNAs that may accompany amplification by 
Example 8 
The Effect of Latexin Expression on Apoptosis 
To determine whether allelic differences in the Chr 3 con-
genic interval affected steady-state apoptosis in HSC popu-
lation, apoptosis was assessed by Annexin V-staining ofbone 
marrow LSK cells. 
FIG. SD illustrates bone marrow LSK cells subject to apo-
ptosis as detected by Annexin V-staining. Top two plots show 
the gates to identify Lin-negative, Sea-l+ and c-kit+(LSK) 
stem cells. Bottom left plots identify Annexin V +, 7 AAD-
negative apoptotic cells in LSK cells. The plots on the right 
are from the thymocyte control for determination of Annexin 
V and 7 AAD quadrants. Plots are from one representative 
animal. 
FIG. SE illustrates Aunexin V-stained LSK populations 
representing steady-state B6 and D2 bone marrow. In FIG. 
SE, a significant variation (P=0.04) in Annexin V-staining in 
LSK populations representing steady-state B6 (2.7%±0.4%) 
and D2 (0.9%±0.2%) bone marrow was observed. The values 
for each strain are the mean (±1 SD) for 8 animals.* indicates 
50 PCR. Triplicate RNA samples, each independently obtained 
from at least 550,000 LSK cells sorted and pooled from a 
minimum of 40 mice, were collected from the four strains. 
Each RNA sample ( 4 strainsx3 replicates= 12 in all) was 
hybridized to an individual microarray chip (MGU Av2 
55 Aff)'metrix). Results obtained from the triplicate chips for 
each strain were analyzed using Aff)'metrix Microarray 
Suite™ software, and were compared using one-way 
AN OVA for each congenic-background strain pair. The num-
ber of genes differentially expressed between B.D Chr3 and 
60 B6 strains was 96 (P<0.05) and between D.B Chr3 and D2 
strains was 84 (P<0.05). Because congenic intervals repre-
sent less than 1% of the entire genome, these numbers are 
commensurate with the 940 differentially expressed genes 
measured between B6 and D2 LSK cells in these experi-
65 ments. 
Table 4 is a list of genes differentially expressed in recip-
rocal Chr 3 congenic and B6, D2 HSCs, as shown below. In 
US 9,284,530 B2 
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Table 4, only 17 genes on 11 different chromosomes were 
mutually inclusive in comparisons between the reciprocal 
congenics and their respective background strains. Of 17 
differentially expressed genes, the D2 and B6 alleles had 
opposite effects on transcription in 9/!7. 'Vl7 were mapped to 
Chr 3, but only 1/4 was located in the consensus congenic 
interval, near the marker of highest linkage in the mapping 
(D3Mit5). The gene was identified to be latexin (Lxn), whose 
expression was upregulated by B6 alleles and down-regulated 
by D2 alleles, a pattern suggested by the linkage analysis. 
26 
ground mice. Results are the average (±1 SD) of 12 measure-
ments derived from 3 independent biological examples. 
Example 11 
Lxn Expression in Undifferentiated and 
Differentiated Hematopoietic Cell Populations 
Lxn expression levels were determined along the differen-
tiation pathway in the hematopoietic system. FIG. 6B illus-
trates quantitation of Lxn transcripts by real-time PCR in 
TABLE4 
Genes differentially expressed in reciprocal Chr 3 congenic and B6. D2 HSCs. 
Chromosomal Entrez 
Probe Set Gene title Gene symbol location (Mb) gene ID 1. Molecular function 
101209 at Fe receptor, IgE, high affinity I, alpha Fcerla 1 (173) 14125 Receptor activity; IgE binding 
polypeptide 
102260 at# Growth factor independent lB Gfilb 2 (28) 14582 ATP binding 
96065 at# Latexin Lxn 3 (67) 17035 Enzyme inhibitor activity 
Metalloendopeptidase inhibitor activity 
92770 at* SlOO calcium binding protein A6 (calcyclin) S100a6 3 (91) 20200 Calcium ion binding; Protein binding 
Growth factor activity 
98600 at# SlOO calcium binding protein All SlOOall 3 (93) 20195 Cytokine activity; Calcium ion binding 
(calizzarin) 
103257 at RIKEN eDNA 4930577M16 gene 4930577 M16Rik 3 (121) 99887 Unknown 
(transmembrane protein 56) (Tmem56) 
94559 - at General transcription factor III A Gtf3a 5 (145) 66596 DNA binding 
102011 at RIKEN eDNA 2610507L03 gene 2610507L03Rik 7 (23) 72140 Unknown 
94286 at RIKEN eDNA 9130011J15 gene 9130011J15 Rik 8 (71) 66818 Unknown -
93498 s at# Amyloid beta (A4) precursor-like protein 2 Aplp2 9 (31) 11804 DNA binding; Protein binding 
Serine-type endopeptidase inhibitor 
activity 
101026 - at* Pituitary tumor-transforming 1 Pttgl 11 (43) 30939 Cysteine protease inhibitor activity 
16128 at# MYB binding protein (P160) la Mybbpla 11 (72) 18432 Protein binding Transcriptional repressor 
activity 
93134 - at Neuronal pentraxin 1 Nptxl 11 (119) 18164 Calcium ion binding 
100391 at Mitogen activated protein kinase 8 Mapk8 14 (29) 26419 Kinase activity; Transferase activity 
100343 at* Tubulin, alpha 1 Tubal 15 (99) 22142 GTPase activity; GTP binding 
Structural constituent of cytoskeleton 
103282 at* RAS, guanyl releasing protein 211 Rasgrp211 19 (6) 19395 II Guanyl-nucleotide exchange factor activity 
similar to calcium and DAG-regulated LOC381240 381240 Calcium ion binding; Diacylglycerol 
guanine nucleotide exchange factor I binding 
Kinase activity 
160391 at Fatty acid desaturase 1 Fads! 19 (9) 76267 Linoleoyl-CoA desaturase activity 
Oxidoreductase activity 
Total RNA isolated from LSK cells in B.D Chr3, D.B Chr3 congenic, and B6, D2 mice was reverse transcribed into eDNA and subsequently used for the synthesis of cRNA, cRNA was 
labeled with biotin and hybridized onto Affymetrix Mouse Genome U74Av2 chip. Gene expression in LSK cells was quantified and averaged from 3 independent experiments. The gene 
expression levels were compared between congenic and repective background mice using one way-ANOVA with a statistical cutoff ofp < 0.05. 17 genes are differentially expressed among 
all4 strains. 
#indicates the genes whose expression is up-regulated by the B6 alleles (high expression in D.B Chr3 and B6 cells) but down-regulated by the D2 alleles (low expression inB.D Chr3 and 
D2 cells), whereas 
*indicate the genes whose expression is upregulated by the D2 alleles but down-regulated by the B6 alleles. 
Example 10 
Determination of Lxn mRNA Levels in 
Hematopoietic Cells 
FIG. 6A illustrates Lxn mRNA expression in congenic 
LSK cells compared with B6 and D2 cells. In FIG. 6A, an 
inverse relationship between Lxn expression and the number 
of CAFC day 35 is observed, which confirms the microarray 
results both qualitatively and quantitatively. As predicted, B6 
alleles in the congenic interval increased Lxn transcripts by 
around 3-fold in LSK cells (P=0.00003), and reduced CAFC 
day35 numbers by more than half. In contrast, D2 alleles 
significantly decreased Lxn expression (P=0.02) and 
increased HSC numbers observed in FIG. 6A. Identical num-
ber (2x105 ) of LSK cells were sorted from each strain and 
Lxn mRNA level in these cells was quantified by real-time 
PCR and compared between congenic and respective back-
peripheral blood leukocytes, whole bone marrow, Lin-nega-
50 tive bone marrow cells, and LSK stem cells. In FIG. 6B, the 
same number of peripheral blood leukocytes, whole bone 
marrow, Lin-negative bone marrow cells, and LSK stem cells 
in each of the four strains were evaluated. Two points are 
noteworthy from the compiled results of three independent 
55 experiments. First, overall levels ofLxn expression per cell in 
each of the populations increase in concert with the content of 
primitive hematopoietic cells. Second, Lxn expression per 
cell in each of the cell populations accurately reflects the 
60 
presence ofB6 (higher expression) or D2 (lower expression) 
alleles in the two congenic and background strains. Lxn 
expression in differentiated peripheral blood leukocytes 
(PB), bone marrow nucleated cells and primitive hematopoi-
etic cell-enriched population, including lineage-negative 
65 cells (Lin-) and HSCs (LSK cells). Lxn mRNA level was 
measured by quantitative real-time PCR and shown as mean 
(±1 SD) (n=12). 
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Quantitative real-time PCR was performed as follows. 
Identical numbers (200,000) of cells were used for total RNA 
extraction in each type of cell population (peripheral blood, 
bone marrow, Lin-negative and LSK cells) for each mouse 
strain. Isolated total RNA was reverse transcribed into eDNA 5 
tions) and heated at 95° C. for 5 minutes. Samples were then 
analyzed by denaturing PAGE (Novex, 10% bis-Tris gel) 
using the equivalent of 4x105 cells per lane. Following elec-
trophoresis, samples were electro-transferred onto immuno-
bilon-P membranes (Millipore, Bedford, Mass., USA), which 
were subsequently blocked and probed with polyclonal rabbit 
anti-Lxn Ig-G antibody at a 1:3000 dilution. This antibody 
was generated from the Lxn-specific amino acid sequence 
CKHNSRLPKEGQAE at the carboxyl terminus, and was 
using random hexamers in a TaqMan® reverse transcription 
solution (PN N8080234) and stored at -20° C. In real-time 
PCR reactions, primer and probe mix for Lxn were purchased 
from Applied Biosystems (Foster city, CA, USA). TaqMan® 
rodent glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (PN 4308313) served as an endogenous control to 
normalize Lxnexpression. PCRreactions were setup accord-
ing to manufacturer's instructions using TaqMan® universal 
PCR master mix (PN 4304437). Analyses of gene expression 
were performed in single reporter assays in an ABI PRISM 
7700 sequence detection system (PE Biosystems, Foster city, 
CA, USA). 
Example 12 
Lxn Protein Levels in Hematopoietic Cells of 
Congenic and Background Strain Mice 
A rabbit anti -mouse LXN antibody was generated from the 
LXN-specific amino acid sequence CKHNSRLPKEGQAE 
at the carboxyl terminus. Because Lxn transcripts were 
present at reasonable levels in unfractionated bone marrow 
and in Lin-negative cells described above in FIG. 6B of 
Example 11, the celllysates derived from these cells were 
employed for Western blot analysis. 
10 produced by Bethyl Laboratories, Inc (Montgomery, Tex.). 
Primary antibodies were detected using alkaline phos-
phatase-conjugated secondary antibodies (Santa Cruz Bio-
technology) and electro-chemifluorescent (ECF) reagent 
15 
(Pharmacia Biotech) according to the manufacturer's instruc-
tions. Blots were visualized using a Molecular Dynamics 
STORM 860 system and Imagequant Software. Following 
the detection and quantification of anti-Lxn antibody, immu-
nobilon-P membrane was sequentially stripped in 40% 
20 methanol and the buffer containing 100 mm ~-mercaptoetha­
nol, 2% sodium dodecyl sulfate and 62.4 mM Tris-HCl to 
remove ECF reaction product and antibodies, respectively. 
The stripped membrane was re-probed with anti-actin anti-
body (Sigma) at 1:500,000 dilution and detected as described 
25 previously. 
Example 13 
Cis-Regulation ofLxn Expression 
30 
FIG. 6C illustrates immunoreactivity between the anti-
mouse LXN antibody and a protein (29 kD) from bone mar-
row cells by a Western Blot. In FIG. 6C, LXN protein (29 
kDdk) was detected by the anti -lLXN antibody using extracts 
prepared from B6 and D2 BM samples. Rabbit anti-mouse 35 
lLXN polyclonal Ig-G antibody was generated from the Lxn-
specific amino acid sequence at the carboxyl terminus. 
Because Lxn expression was detected and quantified in 
LSK cells of the 30 BXD RI strains in the GeneNetwork 
database, a linkage analysis to search for a QTL that could 
modifY Lxn expression was performed. When modifiers of 
Lxn expression were queried using such an approach, sug-
gestive linkage (LRS>9. 6) was obtained to a genomic interval 
spanning from 56.9Mb to 66.8Mb on Chr 3, very close to the 
genomic locations of D3Mit5 and Lxn, a finding consistent 
with cis-regulation. Moreover, the negative additive effects of 
all markers in this genomic interval suggest that the B6 allele 
increases Lxn expression, which corroborates our results 
FIG. 6D illustrates the levels ofLXN protein in whole bone 
marrow and Lin-negative cells. Consistent with the real-time 
PCR results, Lin-negative cells contain more LXN than bone 40 
marrow cells. The cellular content ofLXN in both whole bone 
marrow and Lin-negative cells was significantly higher in 
mouse strains with B6 alleles at and around the Lxn locus. 
The effects of both B6 and D2 Lxn alleles had more promi-
nent effects on either increasing or decreasing Lxn expres-
sion, respectively, when present on opposite strain back-
ground than in the native context. These results suggest an 
influence of other loci acting through epistatic interactions to 
optimize Lxn expression in the two strains. Western blot was 
performed on BM nucleated and Lin- cells. The blots (left) 
and their quantification (right) profiles demonstrate the dif-
ferential expression of Lxn protein in congenic and B6, D2 
mice. Actin is used as the control. The blots are from one 
representative analysis out of 4 independent experiments. 
Western blots were performed as follows. Cell samples 
were lysed at a concentration of 2x107 cells/ml in protein 
lysis buffer containing: 10 mM Tris pH7.5, 50 mM NaCl, 30 
mM sodium pyrophosphate, 50 mM NaF, 5 f.LM ZnC12 and 1% 
Triton X-100, 2.8 ug/ml aprotinin (Sigma), 1 mM phenylm-
ethylsulfonyl fluoride (Sigma), 1 mM sodium vanadate 
(Na3 V04 ) 1 ug/ml pepstatin, and 1 flg/mlleupeptin (Onco-
gene Research, MA, USA). Lysate was incubated on ice for 
30 min, and then centrifuged at 15,000xg for 10 minutes to 
remove debris. The resulting supernatant was then aliquoted 
and stored at -80° C. For Western blot, protein lysates were 
thawed and mixed with running buffer and a reducing agent 
(Novex, San Diego, Calif., USA, per manufacturer's instruc-
from microarray, real-time PCR, and Western blot analyses. 
Therefore, these results not only suggest the existence of a 
regulatory element in the upstream region of the Lxn 
45 sequence, but also corroborate D3Mit5 as a marker, presum-
ably the primary one, for a QTL directly or indirectly respon-
sible for the phenotypes conferred by the Chr 3 QTL. 
FIG. 7A illustrates various QTLs that may be involved in 
the regulation ofLxn expression. In FIG. 7 A, a linkage analy-
50 sis was performed on GeneNetwork to search for a QTL that 
affects Lxn expression. A genomic region on Chr 3 ranging 
from 56.9Mb to 66.8 Mb is shown to be associated with the 
Lxn expression with suggestive LRS values (between gray 
and pink lines). The linked QTL are listed with corresponding 
55 LRS score and additive effect. The single nucleotide poly-
morphism (SNPs) across Chr 3 are shown as tick marks on the 
X-axis. 
FIG. 7B illustrates a CpG island analysis in the upstream 
sequence of Lxn open-reading frame. Analysis of the 
60 upstream sequence of the Lxn open reading frame revealed a 
164 bp CpG island. Nucleotide sequence of Lxn in upstream 
region (-1000 bp) and the first 3 exons (+373 bp) was 
obtained from Ensembl database with ID number ENS-
MUSG0000004 7 557. Transcription start site (TSS) is as indi-
65 cated. CpG island search using MethPrimer software showed 
a 164 bp region ( -138 bp to +26 bp) in the upstream of Lxn 
sequence enriched for CpG repeats. 
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Thus, differential methylation status in the regulatory 
region of Lxn may be involved in the differential expression 
of Lxn. The results also suggest that Lxn may be a potential 
"tumor progenitor gene" which plays an occult role in early 
stages of cancer development. Taken together, each of these 5 
possible pathways may be synergistically or independently 
involved in the regulation of cycling, apoptosis, and/or self-
renewal of HSCs with entrained consequences for its popu-
lation size. 
30 
duction ofhigh-titer helper-free retrovirus was carried out by 
standard procedure in ectotropic Phoenix packaging cells. 
Infection of primary murine bone marrow cells were 
infected as follows. Primary mouse bone marrow cells were 
transduced as previously described with modifications speci-
fied below. Briefly, bone marrow cells were harvested from 
mice treated 4 days previously with 150 mg/kg body weight 
5-fluorouracil (5-FU) (Sigma, St. Louis, Mo.) and cultured 
for 24 hours in Dulbecco's modified eagle's medium 
Example 14 
A Decrease in Stem Cell Numbers By the 
Overexpression of Lxn 
10 (DMEM) supplemented with 10% fetal bovine serum (FBS), 
1% penicillin/streptomycin (Gibco Technologies, Carlsbad, 
Calif.), 50 ng/mL recombinant mouse stem cell factor 
(mSCF), 10 ng/mL mouse interleukin 6 (miL-6), and 10 
ng/mL mouse interleukin 3 (miL-3) (R&D Systems, Minne-
Because D2 and B.D Chr3 congenic mice have lower levels 
ofLxn expression and higher stem cell numbers, Lxn expres-
sion in both strains were enhanced in both strains to test the 
15 apolis, Minn.). The cells were then harvested and slowly 
spread on the top surface of the membrane of a Transwell 
insert (Corning Incorporated Life Sciences, Acton, Mass.) at 
a density of 2x 106 cells per well. The viral supernatants were 
effect ofLxn overexpression on stem cell numbers. 
FIG. SA illustrates a schematic for in vitro infection of 20 
bone marrow cells with retroviral vectors containing either 
GFP or Lxn (Lxn-GFP), and subsequent transplantion into 
irradiated mouse recipients. At ;;:12 weeks following trans-
plant, when all hematopoiesis originated from transplanted 
stem cells, the bone marrow was harvested from the primary 25 
recipients and cells expressing GFP were sorted using flow 
cytometry. The GFP-positive population was isolated to be 
assayed for CAFC day35 content in D2-derived cells and for 
LTRC frequency in B.D Chr3-derived cells. In FIG. SA, the 
structure of Lxn-containing retroviral vector is shown in 30 
which the Lxn-GFP represents the Lxn-containing vector; 
GFP represents the no insert control. 
FIG. SB illustrates results of a Western blot analysis of 
GFP+ cells sorted from the BM of the recipient mice trans-
planted with either Lxn-GFP or GFP-transduced cells. 35 
Expression levels of Lxn protein in bone marrow cells trans-
duced with Lxn-GFP were higher than the expression levels 
ofGFP-transduced cells, confirming that both Lxn transcript 
and protein levels were dramatically increased in Lxn-GFP 
cells. 40 
FIG. SC illustrates results ofCAFC day35 frequency assay 
ofD2 bone marrow cells transduced with either GFP control 
or Lxn-GFP. * P=0.0059 (t-test, one-tail). 
FIG. SD illustrates results of long-term repopulating cells 
(LTRC) frequency assay of B.D Chr.3 congenic BM cells 45 
transduced with either GFP control or Lxn-GFP. * P=0.0458 
(t-test, one-tail). 
In FIGS. SC-SD, the frequency of primitive stem cells was 
significantly reduced (P<O. 05) in the population infected with 
the Lxn-GFP vector relative to cells infected with the GFP 50 
added to the Transwell inserts along with 4 flg/ml of poly-
brene and were cultured with cells for further 48 hours. The 
viral supernatant was changed 3 times during this period of 
time. The recovered cells were then transplanted into sub-
lethally-irradiated (600 Rad) recipient mice at a dose of at 
least 1 x 106 cells per mouse. Around 12 weeks after transplan-
tation, retrovirally-transduced, i.e. GFP positive, bone mar-
row cells were flow cytometrically sorted from primary 
recipient mice using a FACSVantage (Becton-Dickinson) and 
used for CAFC assay and limiting-dilution competitive 
repopulation assay. 
Functional analysis of retrovirally-transduced cells were 
performed as follows. Identical numbers of bone marrow 
cells transduced with either the GFP control vector or the 
Lxn-GFP vector were sorted from the primary recipient mice. 
The CAFC and limiting-dilution competitive repopulation 
assays of these GFP positive cells was performed as described 
above. The HSC frequencies (CAFC day35 and LTRC) were 
calculated and compared to measure the effects ofLxn over-
expression on HSC number. 
Example 15 
Inhibition of Latexin by Exemplary SiRNAs 
FIG. 9A illustrates exemplary SiRNAs transfected into 
NIH3 T3 cells, as described in Example 15. FIG. 9B illustrates 
the results of sequence-specific SiRNA-mediated inhibition 
of latexin mRNA expression in mouse adult stem cells that 
resulted in HSC proliferation and HSC apoptotic inhibition, 
as described in Example 15. For latexin-specific inhibition, 
three exemplary SiRNA were ordered from Ambion (Austin, 
Tex.) identified by the following IDs: SiRNA! (724142) des-
ignated as SEQ ID N0:3 (5'-UCUUCCUGGGAUAU 
CCUCC-3'); SiRNA2 (72510) designated as SEQ ID N0:4 
(5'-UAAGAUGGUACUUGUG CCC-3'); and SiRNA3 
control vector. Approximately a 3-fold decrease in HSC num-
bers in Lxn-overexpressing cells reflects precisely the differ-
ence between two parental B6 and D2 strains. Therefore, 
these results further confirm Lxn as the primary quantitative 
gene negatively regulating HSC numbers. 55 (72605) designated as SEQ ID N0:5 (5'-AAAAUUGU-
CUGGGAUGUC C-3'). A sequence in 3' untranslated region 
was used as a negative control "SiRNA NC" designated as 
SEQ ID N0:6 (5'-AUGCAGCUCGGUACUGUAG-3'). For 
each type of SiRNA, the sense and anti-sense RNA oligo-
Retroviral vectors were constructed as follows. The retro-
viral vector, Sfbeta 91, served as a control and the backbone 
for cloning of Lxn eDNA. It contained the 5'-long terminal 
repeat (LTR) derived from myeloproliferative sarcoma virus 
(MPSV) and a 3'-LTR derived from spleen focus forming 
virus (SFFV). The internal ribosomal entry site sequence 
derived from the encephalomyocarditis virus was used for 
simultaneous translation of gene insert and the gene for 
enhanced green fluorescent protein (GFP). The Lxn eDNA 
sequence was cloned upstream of the IRES of the Sfbeta91 65 
vector (MPSV-IRES-GFP-SFFV) to create a recombinant 
Lxn-carrying vector (MPSV-Lxn-IRES-GFP-SFFV). Pro-
60 nucleotides were diluted to 200 uM concentration. For the 
annealing reaction, 40 ul of each oligonucleotide were mixed 
with 20 ul of annealing buffer (Ambion) and heated for 1 
minute at 90° C., followed by an incubation for 1 hour at 37° 
C. For the transfection, the double-stranded RNA oligonucle-
otides were further diluted at 20 pmol/ul concentration. For 
the transfection of NIH3T3 cells with SiRNA and reported 
GFP plasmid, approximately 4xl05 NIH3T3 cells were seed 
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in a 6-well plate and were grown overnight in Iscove's Modi-
fied Dulbecco's Medium (IMDM) (Invitrogen) containing 
10% fetal bovine serum (FBS). The cells were 8090% con-
fluent at the time oftransfection. For each transfection/well, 
approximately 9 ul Lipofectamine™ 2000 (Invitrogen) were 
diluted with 250 ul Opti-MEM I Reduced Serum Medium 
(Gibco) and incubated for 5 minutes at room temperature. 
Approximately 2 ug of reporter GFP plasmid and 200 f.tmol of 
SiRNA were also diluted in 250 ul ofOpti-MEM I Reduced 
Serum Medium. The diluted Lipofectamine™ 2000 were 10 
combined with the diluted SiRNA and the reporter plasmid. 
The mixture was incubated for 20 minutes at room tempera-
ture. The NIH3T3 cells were washed twice with PBS (Invit-
rogen) and incubated with 500 ul of RNA-reporter plasmid-
Lipofectamine™ 2000 complex in each well. 12-15 hours 15 
after incubation, the medium was changed to IMDM plus 
10% FBS. The cells were detached by trypson and resus-
pended into 5 ug/mL propidium (PI) solution. For sorting 
transfected (GFP+) cells, flow cytometric analysis was per-
formed on a dual-laser FACSVantage (Becton Dickinson 20 
Immunocytometry Systems, San Jose, Calif.) to select PI 
negative and GFP positive cells. 
Quantitative real-time PCR was performed in the follow-
ing manner. Identical numbers (200,000) of cells were used 
for total RNA extraction in cells transfected with 3 SiRNAs 25 
and negative control RNAs. Isolated total RNA was reverse 
transcribed into eDNA using random hexamers in a Taq-
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 
<210> SEQ ID NO 1 
<211> LENGTH, 1113 
<212> TYPE, DNA 
<213> ORGANISM, human 
<400> SEQUENCE, 1 
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Man® reverse transcription solution (PN N8080234) and 
stored at -20° C. Quantitative real-time PCR analyses of 
selected genes were performed in single reporter assays with 
anABI PRISM 7700 sequence detection system (PE Biosys-
tems, Foster city, CA, USA). PCR reactions were set up 
according to manufacturer's instructions using TaqMan® 
universal PCR master mix (PN 430443 7), and the primer and 
probe mixes for each tested gene were purchased from 
Applied Biosystems (Foster city, CA, USA). TaqMan® 
rodent glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH (PN 4308313) served as an endogenous control to 
normalize gene expression. The analysis of gene expression 
was performed by the relative standard curve method. In 
brief, standard curves were prepared for the GAPDH control 
and for each of tested genes, and the amount of GAPDH 
control and test gene were determined from the standard 
curve. A normalized test gene value was determined relative 
to GAPDH expression. Each biological sample was obtained 
from at least 5 mice, and each sample was run with at least 5 
replicates within an experiment. Three replicate biological 
experiments were performed in each strain. 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 
departing from the spirit and the scope of the invention. 
Accordingly, the invention is not limited except as by the 
appended claims. 
agaagcagtc agcccagggc tctcggatgc agggagcctg ggcccaaaca gcagcttccg 60 
gagtcggaag gagctgagga agaagacaga ctgaaggagc ttgcgacttt tccgcctcgg 120 
caaccggacc cagcagcaag caggacgggc ggcgctctgc tactggtccc gttaagccag 180 
agtagcccaa gccctgaagt cactgctcat ccggaatgga aatcccgccg accaactacc 240 
cagcctccag ggcggccttg gtggcacaga actacatcaa ctaccagcag gggaccccgc 300 
acagggtgtt tgaggtgcag aaggtcaaac aagccagcat ggaggatatt ccaggaagag 360 
gacataagta tcgccttaaa tttgctgttg aagaaattat acaaaaacaa gttaaggtga 420 
actgcacagc tgaagtactt tacccttcaa cgggacaaga aactgcacca gaagtcaact 480 
tcacatttga aggagaaact ggaaagaatc cagatgaaga agacaacaca ttttatcaaa 540 
gacttaagtc catgaaggaa ccgctagaag cacaaaatat tccagacaat tttggaaatg 600 
tatctccaga aatgacgctc gttctacatt tagcctgggt tgcctgtggt tatataatat 660 
ggcaaaattc tactgaagac acatggtata aaatggtaaa aattcaaact gtcaagcaag 720 
tgcaaagaaa tgatgacttt attgaattag actacaccat tctacttcat aatatagcat 780 
ctcaggagat tattccctgg caaatgcaag ttctctggca tccacaatac ggcactaaag 840 
taaaacataa tagccgtctg ccaaaggaag tacaactgga ataaacaaaa accctaacac 900 
tggaagtgta aacatgtcta ttgatgtgta tgccaatttc actggcatct agcttatgag 960 
gccaaataat cccaaagtgt cactttatat aaatgtcttg attacagtat agaactttat 1020 
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agagtccata atacaaagta tcactacata aaaatgtctt taaaacagta atagtggtat 
gtatatccaa aataaaaagc ttcaatttca gee 
<210> SEQ ID NO 2 
<211> LENGTH, 222 
<212> TYPE, PRT 
<213> ORGANISM, human 
<400> SEQUENCE, 2 
Met Glu Ile Pro Pro Thr Asn Tyr Pro 
1 5 
Ala Gln Asn Tyr Ile Asn Tyr Gln Gln 
20 25 
Ala Ser Arg Ala Ala Leu Val 
10 15 
Gly Thr Pro His Arg Val Phe 
30 
Glu Val Gln Lys Val Lys Gln Ala Ser Met Glu Asp Ile Pro Gly Arg 
35 40 45 
Gly His Lys Tyr Arg Leu Lys Phe Ala Val Glu Glu Ile Ile Gln Lys 
50 55 60 
Gln Val Lys Val Asn Cys Thr Ala Glu Val Leu Tyr Pro Ser Thr Gly 
65 70 75 80 
Gln Glu Thr Ala Pro Glu Val Asn Phe Thr Phe Glu Gly Glu Thr Gly 
85 90 95 
Lys Asn Pro Asp Glu Glu Asp Asn Thr Phe Tyr Gln Arg Leu Lys Ser 
100 105 110 
Met Lys Glu Pro Leu Glu Ala Gln Asn Ile Pro Asp Asn Phe Gly Asn 
115 120 125 
Val Ser Pro Glu Met Thr Leu Val Leu His Leu Ala Trp Val Ala Cys 
130 135 140 
Gly Tyr Ile Ile Trp Gln Asn Ser Thr Glu Asp Thr Trp Tyr Lys Met 
145 150 155 160 
Val Lys Ile Gln Thr Val Lys Gln Val Gln Arg Asn Asp Asp 
165 170 
Glu Leu Asp Tyr Thr Ile Leu Leu His Asn Ile Ala Ser Gln 
180 185 190 
Ile Pro Trp Gln Met Gln Val Leu Trp His Pro Gln Tyr Gly 
195 200 205 
Val Lys His Asn Ser Arg Leu Pro Lys Glu Val Gln Leu Glu 
210 215 220 
<210> SEQ ID NO 3 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, mouse 
<400> SEQUENCE, 3 
ucuuccuggg auauccucc 
<210> SEQ ID NO 4 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, mouse 
<400> SEQUENCE, 4 
uaagauggua cuugugccc 
Phe Ile 
175 
Glu Ile 
Thr Lys 
34 
1080 
1113 
19 
19 
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-continued 
<210> SEQ ID NO 5 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, mouse 
<400> SEQUENCE, 5 
aaaauugucu gggaugucc 
<210> SEQ ID NO 6 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, mouse 
<400> SEQUENCE, 
augcagcucg guacuguag 
We claim: 
1. A method for reconstituting a recipient host with a popu-
lation of hematopoietic stem cells (HSCs) generated in vivo, 
the method comprising: administering to the recipient host a 
pharmaceutical composition comprising an antagonist that 
reduces the expression and/or the activity oflatexin, wherein 
the recipient host is affected with at least one condition 
selected from the group consisting of: a disease of the bone 
marrow, a cancerofthe blood, a cancerofthe bone marrow, an 
immunological disorder, thalassemia major, sickle-cell dis-
ease, and myelodysplastic syndrome, wherein the antagonist 
can promote HSC proliferation by at least 25%, wherein 
19 
19 
latexin includes a latexin polynucleotide variant and/or a 
latexin polypeptide variant that interacts with the antagonist, 
25 and wherein the latexin polynucleotide variant has at least 
95% sequence identity to the full length of SEQ ID NO: 1 and 
the latexin polypeptide variant has 100% sequence identity to 
the full length of SEQ ID NO: 2. 
2. The method of claim 1, wherein the recipient host is 
30 affected with at least one condition selected from the group 
consisting of leukemia, lymphoma, and multiple myeloma. 
3. The method of claim 1, wherein the latexin polynucle-
otide variant encodes SEQ ID NO: 2. 
* * * * * 
